<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: uncertainties", fill: "#483c32"},
{source: "1: uncertainties", target: "1: financial condition", fill: "#483c32"},
{source: "1: financial condition", target: "1: operations", fill: "#483c32"},
{source: "1: uncertainties", target: "7: regulatory approval", fill: "#fada5e"},
{source: "7: regulatory approval", target: "7: future revenues", fill: "#fada5e"},
{source: "7: regulatory approval", target: "9: On September ", fill: "#f0fff0"},
{source: "9: On September ", target: "9: which provides", fill: "#f0fff0"},
{source: "9: which provides", target: "9: approvable pending", fill: "#f0fff0"},
{source: "9: approvable pending", target: "9: requested analysis", fill: "#f0fff0"},
{source: "9: requested analysis", target: "9: transfusion requirements", fill: "#f0fff0"},
{source: "9: transfusion requirements", target: "9: patients enrolled", fill: "#f0fff0"},
{source: "9: patients enrolled", target: "9: Phase III ", fill: "#f0fff0"},
{source: "9: Phase III ", target: "9: trial submission", fill: "#f0fff0"},
{source: "9: trial submission", target: "9: completion", fill: "#f0fff0"},
{source: "9: completion", target: "9: labeling discussions", fill: "#f0fff0"},
{source: "9: On September ", target: "23: If Dacogen ", fill: "#d40000"},
{source: "23: If Dacogen ", target: "23: regulatory approval", fill: "#d40000"},
{source: "23: regulatory approval", target: "23: United States or Europe ", fill: "#d40000"},
{source: "23: United States or Europe ", target: "23: physicians may", fill: "#d40000"},
{source: "23: physicians may", target: "23: readily accept", fill: "#d40000"},
{source: "23: readily accept", target: "23: which would", fill: "#d40000"},
{source: "23: which would", target: "23: lower royalty revenue from", fill: "#d40000"},
{source: "23: lower royalty revenue from", target: "23: currently conducting clinical trials with", fill: "#d40000"},
{source: "23: currently conducting clinical trials with", target: "23: Orathecin ", fill: "#d40000"},
{source: "23: Orathecin ", target: "23: combination", fill: "#d40000"},
{source: "23: If Dacogen ", target: "24: clinical trials", fill: "#79443b"},
{source: "24: clinical trials", target: "24: support regulatory approval", fill: "#79443b"},
{source: "24: clinical trials", target: "38: development activities", fill: "#882d17"},
{source: "38: development activities", target: "38: primarily from private placements", fill: "#882d17"},
{source: "38: primarily from private placements", target: "38: public offerings", fill: "#882d17"},
{source: "38: public offerings", target: "38: milestone payments", fill: "#882d17"},
{source: "38: milestone payments", target: "38: revenues generated primarily from sales", fill: "#882d17"},
{source: "38: revenues generated primarily from sales", target: "38: Nipent ", fill: "#882d17"},
{source: "38: Nipent ", target: "38: United States ", fill: "#882d17"},
{source: "38: United States ", target: "38: patients with", fill: "#882d17"},
{source: "38: patients with", target: "38: hairy cell leukemia", fill: "#882d17"},
{source: "38: development activities", target: "42: profitability depends primarily on", fill: "#fff600"},
{source: "42: profitability depends primarily on", target: "42: following factors", fill: "#fff600"},
{source: "42: following factors", target: "42: regulatory approval", fill: "#fff600"},
{source: "42: regulatory approval", target: "42: successful commercialization", fill: "#fff600"},
{source: "42: successful commercialization", target: "42: MGI ", fill: "#fff600"},
{source: "42: MGI ", target: "42: indications", fill: "#fff600"},
{source: "42: indications", target: "42: proprietary", fill: "#fff600"},
{source: "42: proprietary", target: "42: development", fill: "#fff600"},
{source: "42: development", target: "42: infrastructure", fill: "#fff600"},
{source: "42: infrastructure", target: "42: successfully", fill: "#fff600"},
{source: "42: successfully", target: "42: inlicensing", fill: "#fff600"},
{source: "42: inlicensing", target: "42: acquisition", fill: "#fff600"},
{source: "42: acquisition", target: "42: development efforts", fill: "#fff600"},
{source: "42: development efforts", target: "42: clinical trials", fill: "#fff600"},
{source: "42: clinical trials", target: "42: competitions ability", fill: "#fff600"},
{source: "42: competitions ability", target: "42: market competing", fill: "#fff600"},
{source: "42: market competing", target: "42: expenses associated with", fill: "#fff600"},
{source: "42: expenses associated with", target: "42: manufacturing distributing", fill: "#fff600"},
{source: "42: manufacturing distributing", target: "42: products as well as general", fill: "#fff600"},
{source: "42: products as well as general", target: "42: administrative costs", fill: "#fff600"},
{source: "42: administrative costs", target: "42: expenses associated with entering into licensing", fill: "#fff600"},
{source: "42: expenses associated with entering into licensing", target: "42: collaborative agreements", fill: "#fff600"},
{source: "42: collaborative agreements", target: "42: commercial sales", fill: "#fff600"},
{source: "42: commercial sales", target: "42: products once regulatory approvals", fill: "#fff600"},
{source: "42: profitability depends primarily on", target: "45: will continue", fill: "#40826d"},
{source: "45: will continue", target: "45: resources on expanding", fill: "#40826d"},
{source: "45: resources on expanding", target: "45: pipeline strengthening", fill: "#40826d"},
{source: "45: pipeline strengthening", target: "45: commercialization efforts", fill: "#40826d"},
{source: "45: commercialization efforts", target: "45: new avenues", fill: "#40826d"},
{source: "45: new avenues", target: "45: operations", fill: "#40826d"},
{source: "45: operations", target: "45: market selling", fill: "#40826d"},
{source: "45: market selling", target: "45: distributing", fill: "#40826d"},
{source: "45: distributing", target: "45: future products", fill: "#40826d"},
{source: "45: future products", target: "45: conducting research", fill: "#40826d"},
{source: "45: conducting research", target: "45: development", fill: "#40826d"},
{source: "45: development", target: "45: product candidates", fill: "#40826d"},
{source: "45: will continue", target: "START_HERE", fill: "#40826d"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Offer peace proposal</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Expel</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Demonstrate</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Covert monitoring</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_on_Ayurveda">Clinical trials on Ayurveda</a></td>
      <td>Clinical trials on Ayurveda refers to any clinical trials done on Ayurvedic treatment. Ayurveda is a traditional medicine system in India and like other cultural medical practices includes both conventional medicine and also complementary and alternative medicine.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>SUPERGEN INC      ITEM 1A RISK FACTORS       The  following  section  lists  some,  but  not  all, of the risks and     <font color="blue">uncertainties</font> that may have a material adverse effect on our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>You <font color="blue">should carefully</font> consider     these risks in evaluating our company and business</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">operations</font>     may  be  impaired if any of the <font color="blue"><font color="blue">following risks</font> actually</font> occur, and by     <font color="blue">additional</font>  risks  and <font color="blue">uncertainties</font> that we do not know of or that we     currently consider immaterial</td>
    </tr>
    <tr>
      <td>In such case, the <font color="blue">trading price</font> of our common     <font color="blue">stock could decline</font></td>
    </tr>
    <tr>
      <td>This report also contains forward-looking statements that <font color="blue">involve risks</font> and     <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>Our  actual results <font color="blue">could differ <font color="blue">materially</font> from</font> those     anticipated  in  the forward-looking statements as a result of certain     factors, including the <font color="blue">risks described</font> below and elsewhere in this report</td>
    </tr>
    <tr>
      <td>Risks Related to Dacogen, <font color="blue">Orathecin </font>and <font color="blue">Nipent     </font>  If we do not receive <font color="blue"><font color="blue">regulatory</font> approval</font> for Dacogen, our <font color="blue">future revenues</font>     may be limited and our business would be harmed</td>
    </tr>
    <tr>
      <td>Our  NDA  submission for Dacogen was accepted for <font color="blue">filing by</font> the FDA on     <font color="blue">December </font>31, 2004</td>
    </tr>
    <tr>
      <td><font color="blue">On September </font>1, 2005, we received an <font color="blue">Approvable Letter</font>     for Dacogen from the FDA, <font color="blue">which provides</font> that Dacogen is <font color="blue">approvable pending</font>     the FDA’s review of a <font color="blue">requested analysis</font> of the <font color="blue">transfusion <font color="blue">requirements</font></font> of     <font color="blue">patients enrolled</font> in the completed <font color="blue">Phase III </font>trial, submission of certain     other information, and <font color="blue">completion</font> of <font color="blue">labeling discussions</font></td>
    </tr>
    <tr>
      <td>We completed the     <font color="blue">collection</font> and analysis of the <font color="blue">data requested by</font> the FDA and submitted our     response <font color="blue">to the <font color="blue">Approvable Letter</font> </font>on November 15, 2005</td>
    </tr>
    <tr>
      <td>On <font color="blue">December </font>15,     2005,  the FDA accepted our <font color="blue"><font color="blue">resubmission</font> as</font> a complete response to the     <font color="blue">Approvable Letter</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">resubmission</font> has <font color="blue">been classified by</font> the FDA as a     Class 2 response, <font color="blue">and the FDA </font>established a <font color="blue">user fee goal date</font> to review the     <font color="blue">response by</font> May 15, 2006</td>
    </tr>
    <tr>
      <td>We believe this response confirms the clinical     benefit  <font color="blue">of Dacogen </font>compared to <font color="blue">supportive care with</font> regard to overall     response  rate,  duration of response, and <font color="blue">transfusion independence</font> in     <font color="blue">patients with</font> MDS       Our European subsidiary, EuroGen Pharmaceuticals Ltd, submitted an MAA for     Dacogen to the EMEA, <font color="blue">which submission</font> was accepted for review on October 25,     2004</td>
    </tr>
    <tr>
      <td><font color="blue">MGI and SuperGen </font>determined that <font color="blue">additional</font> clinical data will be     required to continue the review of <font color="blue">Dacogen in Europe</font></td>
    </tr>
    <tr>
      <td>Therefore, we have     withdrawn the MAA for Dacogen</td>
    </tr>
    <tr>
      <td>This revision in the European <font color="blue">regulatory</font>     strategy for Dacogen does not affect <font color="blue">regulatory</font> strategies being pursued in     the US       28     ______________________________________________________________________       <font color="blue">MGI and SuperGen </font><font color="blue">will continue</font> to work with European <font color="blue">regulatory</font> <font color="blue">authorities</font>     to determine the information required to support a <font color="blue">resubmission</font> of the     <font color="blue">application</font>, and anticipate <font color="blue">resubmitting</font> the <font color="blue">application</font> at a later date</td>
    </tr>
    <tr>
      <td>MGI anticipates that next steps in the European <font color="blue">regulatory</font> strategy may be     finalized in <font color="blue"><font color="blue">collaboration</font> with</font> a partner</td>
    </tr>
    <tr>
      <td><font color="blue">If Dacogen </font>is <font color="blue">unsuccessful</font> for any reason, including if the results of the     Phase  III  study  are  deemed  insufficient <font color="blue">from either</font> a clinical or     <font color="blue">statistical basis by</font> the FDA, our <font color="blue">future revenues</font> would be limited and our     business would be harmed</td>
    </tr>
    <tr>
      <td>Additionally, we might be forced to <font color="blue">substantially</font>     <font color="blue">scale down</font> our <font color="blue">operations</font> or <font color="blue">sell certain</font> of our assets, and it is likely     the price of our <font color="blue">stock would decline precipitously</font></td>
    </tr>
    <tr>
      <td>In addition, pursuant to our <font color="blue">license <font color="blue">agreement</font> with</font> MGI, we are expecting to     receive <font color="blue">payments from</font> MGI in <font color="blue">connection</font> with the <font color="blue">achievement</font> of certain     <font color="blue">commercialization</font> <font color="blue">milestones</font></td>
    </tr>
    <tr>
      <td>If these <font color="blue">commercialization</font> <font color="blue">milestones</font> are not     met, we will not receive these payments and our <font color="blue">financial condition</font> and     business would be harmed</td>
    </tr>
    <tr>
      <td>Even if we receive <font color="blue"><font color="blue">regulatory</font> approval</font> <font color="blue">of Dacogen </font>for the treatment of     <font color="blue">patients with</font> myelodysplastic syndromes, Dacogen may not be <font color="blue">commercially</font>     successful</td>
    </tr>
    <tr>
      <td><font color="blue">If Dacogen </font>receives <font color="blue"><font color="blue">regulatory</font> approval</font> in the <font color="blue"><font color="blue">United States</font> </font>or Europe,     patients and <font color="blue">physicians may</font> not <font color="blue">readily accept</font> it, <font color="blue">which would</font> result in     lower than projected sales and substantial harm to our business through the     receipt of <font color="blue">lower royalty <font color="blue">revenue from</font></font> MGI       We are <font color="blue">currently conducting <font color="blue"><font color="blue">clinical trial</font>s</font> with</font> <font color="blue">Orathecin </font>as a <font color="blue">combination</font>     therapy</td>
    </tr>
    <tr>
      <td>If these <font color="blue"><font color="blue">clinical trial</font>s</font> do not support <font color="blue"><font color="blue">regulatory</font> approval</font>, our     business may be harmed</td>
    </tr>
    <tr>
      <td><font color="blue">In January </font>2005, we announced the withdrawal of our NDA for <font color="blue">Orathecin </font>based     <font color="blue">on feedback from</font> the FDA that the <font color="blue">data package</font> we submitted in support of     the drug would not be sufficient to gain <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>However, we     are continuing to conduct <font color="blue"><font color="blue">clinical trial</font>s</font> with <font color="blue">Orathecin </font>as a <font color="blue">combination</font>     <font color="blue">therapy while</font> we review and determine whether or not we <font color="blue">will continue</font> to     pursue <font color="blue"><font color="blue">regulatory</font> approval</font> for Orathecin</td>
    </tr>
    <tr>
      <td>Clinical trials are expensive to     conduct,  time-consuming  and  have  <font color="blue">uncertain outcomes</font></td>
    </tr>
    <tr>
      <td>We will incur     substantial <font color="blue">expense while conducting</font> these studies, and if we are unable to     complete  the studies, or if the results of the studies do not support     <font color="blue"><font color="blue">regulatory</font> approval</font> of <font color="blue">Orathecin </font>as a <font color="blue">combination</font> therapy, we will incur     <font color="blue">significant</font> operating losses and our business will be harmed</td>
    </tr>
    <tr>
      <td>Even  if  we receive <font color="blue"><font color="blue">regulatory</font> approval</font> of <font color="blue">Orathecin </font>as a <font color="blue">combination</font>     therapy, <font color="blue">Orathecin </font>may not be <font color="blue">commercially</font> successful</td>
    </tr>
    <tr>
      <td>If  <font color="blue">Orathecin </font> receives  <font color="blue"><font color="blue">regulatory</font> approval</font> in the <font color="blue"><font color="blue">United States</font> </font>as a     <font color="blue">combination</font> therapy, patients and <font color="blue">physicians may</font> not <font color="blue">readily accept</font> it,     <font color="blue">which would</font> result in lower than projected sales and substantial harm to our     business</td>
    </tr>
    <tr>
      <td><font color="blue">Acceptance </font>will be a function of <font color="blue">Orathecin </font>being <font color="blue">clinically useful</font>     and <font color="blue">demonstrating</font> superior <font color="blue">therapeutic</font> effect with an acceptable side effect     <font color="blue">profile as compared</font> to <font color="blue">currently existing</font> or <font color="blue">future <font color="blue">treatments</font></font></td>
    </tr>
    <tr>
      <td>In addition,     even if <font color="blue">Orathecin </font>does achieve <font color="blue">market <font color="blue">acceptance</font></font>, we may not be able to     maintain that <font color="blue">market <font color="blue">acceptance</font></font> over time if <font color="blue">new products</font> are introduced     that  are  more  favorably received than <font color="blue">Orathecin </font>or render <font color="blue">Orathecin </font>    obsolete</td>
    </tr>
    <tr>
      <td>If we are unable to expand our <font color="blue">clinical support</font> for use of Nipent to treat     <font color="blue">additional</font> diseases our revenues will not expand as planned</td>
    </tr>
    <tr>
      <td>Part of our strategy involves expanding the market <font color="blue">opportunities</font> for our     <font color="blue">approved drugs</font>, including Nipent, by seeking <font color="blue">clinical support</font> of their use     for  treatment  of <font color="blue">patients with</font> <font color="blue">additional</font> diseases</td>
    </tr>
    <tr>
      <td>We are currently     marketing Nipent for the treatment of <font color="blue">patients with</font> <font color="blue">hairy cell leukemia</font>, and     <font color="blue">revenues from selling</font> Nipent has provided the majority of our <font color="blue">annual product</font>     <font color="blue">revenues over</font> the <font color="blue">past three years</font></td>
    </tr>
    <tr>
      <td>We are conducting a series of clinical     trials with Nipent, including <font color="blue">Phase IV </font>trials for CLL, NHL, cutaneous and       29     ______________________________________________________________________       peripheral T-cell lymphomas and Phase II/III studies for GvHD If our <font color="blue">Nipent     </font><font color="blue"><font color="blue">clinical trial</font>s</font> are not successful, we will not be able to increase our     <font color="blue">revenue from</font> Nipent</td>
    </tr>
    <tr>
      <td>Risks Related to Our Financial Condition and Common Stock       We have a history of operating losses and we expect to continue to incur     losses for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>Since inception, we have funded our research and <font color="blue"><font color="blue">development</font> <font color="blue">activities</font></font>     <font color="blue">primarily from private placements</font> and <font color="blue">public offerings</font> of our securities,     <font color="blue">milestone payments</font> and <font color="blue">revenues generated primarily from sales</font> of Nipent,     which is marketed in the <font color="blue"><font color="blue">United States</font> </font>for the treatment of <font color="blue">patients with</font>     <font color="blue">hairy cell leukemia</font></td>
    </tr>
    <tr>
      <td>Our substantial research and <font color="blue"><font color="blue">development</font> expenditures</font>     and  limited revenues have resulted in <font color="blue">significant</font> net losses</td>
    </tr>
    <tr>
      <td>We have     incurred  cumulative  losses  of dlra348dtta0 million from inception through     <font color="blue">December </font>31, 2005, and our products have not <font color="blue">generated sufficient revenues</font>     to support our business during that time</td>
    </tr>
    <tr>
      <td>We expect to continue to incur     substantial operating losses at least through 2007 and may never achieve     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Whether we achieve <font color="blue">profitability</font> depends primarily on the <font color="blue">following factors</font>:       ·        our ability to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for Dacogen and the     successful <font color="blue">commercialization</font> <font color="blue">of Dacogen </font>by MGI;       ·       our ability to develop and obtain <font color="blue"><font color="blue">regulatory</font> approval</font> of Nipent for     <font color="blue">indications</font> other than <font color="blue">hairy cell leukemia</font>;       ·       our ability to bring to market other <font color="blue">proprietary</font> products that are     advancing through our internal clinical <font color="blue">development</font> <font color="blue">infrastructure</font>;       ·       our ability to <font color="blue">successfully</font> expand our <font color="blue">product pipeline</font> through     in-licensing and product <font color="blue">acquisition</font>;       ·       our ability to <font color="blue">successfully</font> market Nipent in Europe as planned;       ·       our research and <font color="blue">development</font> efforts, including the timing and costs     of <font color="blue"><font color="blue">clinical trial</font>s</font>;       ·       our competition’s ability to develop and bring to <font color="blue">market competing</font>     products;       ·        our  ability  to  control  costs and <font color="blue">expenses associated with</font>     <font color="blue">manufacturing</font>, <font color="blue">distributing</font> and selling our products, as well as general and     <font color="blue">administrative costs</font> related to conducting our business;       ·       costs and <font color="blue">expenses associated with</font> entering into licensing and other     <font color="blue"><font color="blue">collaborative</font> <font color="blue">agreement</font>s</font>; and       ·       delays in production or inadequate <font color="blue"><font color="blue">commercial sale</font>s</font> of Dacogen,     <font color="blue">Orathecin </font>and other products, once <font color="blue"><font color="blue">regulatory</font> approval</font>s have been received</td>
    </tr>
    <tr>
      <td>Our products and <font color="blue"><font color="blue">product candidate</font>s</font>, even if <font color="blue">successfully</font> developed and     approved, may not <font color="blue">generate sufficient</font> or <font color="blue">sustainable revenues</font> to <font color="blue">enable us</font>     to achieve or sustain <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>30     ______________________________________________________________________       We  will  require  <font color="blue">additional</font>  funding to expand our <font color="blue">product pipeline</font>,     strengthen our <font color="blue">commercialization</font> efforts and expand our European <font color="blue">operations</font>,     and  if  we  are  unable to raise the <font color="blue"><font color="blue">necessary</font> capital</font> or to do so on     acceptable terms, our planned expansion and <font color="blue">continued chances</font> of  survival     could be harmed</td>
    </tr>
    <tr>
      <td>We <font color="blue">will continue</font> to spend substantial <font color="blue">resources on expanding</font> our product     pipeline, strengthening our <font color="blue">commercialization</font> efforts for our existing     products,  developing <font color="blue">new avenues</font> of revenue for Nipent, scaling-up of     European <font color="blue">operations</font> to market, selling and <font color="blue">distributing</font> our existing and     <font color="blue">future products</font>, and <font color="blue">conducting research</font> and <font color="blue">development</font>, including clinical     trials for other products and <font color="blue"><font color="blue">product candidate</font>s</font></td>
    </tr>
    <tr>
      <td>We anticipate that our     capital  resources  will  be  adequate  to fund <font color="blue">operations</font> and capital     expenditures through 2006</td>
    </tr>
    <tr>
      <td>However, if we experience <font color="blue">unanticipated cash</font>     <font color="blue">requirements</font> during this period, we could require <font color="blue">additional</font> funds much     sooner</td>
    </tr>
    <tr>
      <td>We <font color="blue">may raise money by</font> the sale of our <font color="blue">equity securities</font> or debt, or     the exercise of <font color="blue">outstanding warrants</font> and <font color="blue">stock options by</font> the holders of     <font color="blue">such warrants</font> and options</td>
    </tr>
    <tr>
      <td>However, <font color="blue">given uncertain market conditions</font> and     the <font color="blue">volatility</font> of our stock price, we may not be able to sell our securities     in <font color="blue">public offerings</font> or private placements at prices and/or on terms that are     favorable  to  us,  if at all</td>
    </tr>
    <tr>
      <td>Also, the dilutive effect of <font color="blue">additional</font>     <font color="blue">financings</font> could <font color="blue">adversely</font> affect our per share results</td>
    </tr>
    <tr>
      <td>We <font color="blue">may also choose</font>     to obtain <font color="blue">funding through licensing</font> and other <font color="blue"><font color="blue">contractual</font> <font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>For     example, we <font color="blue">recently licensed</font> the <font color="blue">worldwide rights</font> to the <font color="blue">development</font>,     <font color="blue">commercialization</font> and <font color="blue">distribution</font> of <font color="blue">Dacogen to MGI Such </font><font color="blue">arrangements may</font>     require  us  to <font color="blue">relinquish</font> our rights to our <font color="blue">technologies</font>, products or     <font color="blue">marketing territories</font>, or to <font color="blue">grant licenses on terms</font> that are not favorable     to us</td>
    </tr>
    <tr>
      <td>If we fail to obtain <font color="blue">adequate funding</font> in a <font color="blue">timely manner</font>, or at all,     we will be forced to scale back our product <font color="blue"><font color="blue">development</font> <font color="blue">activities</font></font>, or be     forced to cease our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue"><font color="blue">collaborative</font> relationship with</font> MGI may not produce the financial     benefits that we are anticipating, <font color="blue">which could</font> cause our business to suffer</td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">raising money by selling</font> our <font color="blue">equity securities</font> to MGI in     <font color="blue">connection</font> with the license <font color="blue">agreement</font>, we also expect to record <font color="blue">development</font>     and license <font color="blue">revenue from</font> payments made to us by MGI upon the <font color="blue">achievement</font> of     <font color="blue">regulatory</font> and <font color="blue">commercialization</font> <font color="blue">milestones</font></td>
    </tr>
    <tr>
      <td>However, we may fail to achieve     these <font color="blue">milestones</font>, either because we are unable to secure <font color="blue"><font color="blue">regulatory</font> approval</font>     <font color="blue">of Dacogen </font>or due to our <font color="blue">inability</font> to expend the resources to <font color="blue">commence sales</font>     <font color="blue">of Dacogen </font><font color="blue">as prescribed by</font> the license <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>In addition, the license     <font color="blue">agreement</font>  contemplates  that MGI <font color="blue">will pay us</font> (i) a certain portion of     revenues  payable to MGI as a result of MGI <font color="blue">sublicensing</font> the rights to     market, sell and/or distribute Dacogen, to the <font color="blue">extent such revenues</font> are in     excess of the <font color="blue">milestone payments</font>, and (ii) a 20prca royalty increasing to a     maximum of 30prca on annual worldwide net sales of Dacogen</td>
    </tr>
    <tr>
      <td>We cannot guarantee     that  we  will  ever  receive these payments, as MGI may choose not to     sublicense Dacogen at all, nor can we be assured that MGI will expend the     resources to sell Dacogen worldwide, or be successful in doing so</td>
    </tr>
    <tr>
      <td>Our  equity  <font color="blue">investment</font> in AVI <font color="blue">exposes us</font> to <font color="blue">equity price risk</font> and any     <font color="blue"><font color="blue">impairment</font> charge would affect</font> our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We  are  exposed to <font color="blue">equity price risk</font> on our equity <font color="blue">investment</font> in AVI     <font color="blue">Currently </font>we own 2cmam684cmam211 shares of AVI During the year ended <font color="blue">December </font>31,     2004, we recorded a write-down of dlra7dtta9 million related to an other than     <font color="blue">temporary decline</font> in the value of our equity <font color="blue">investment</font> in AVI, resulting in     a  reduction of our cost basis in the AVI shares</td>
    </tr>
    <tr>
      <td>Under our <font color="blue">accounting</font>     policy, marketable <font color="blue">equity securities</font> are presumed to be impaired if their     <font color="blue">fair value</font> is less than their cost basis for more <font color="blue">than six months</font>, absent     <font color="blue">compelling evidence</font> to the contrary</td>
    </tr>
    <tr>
      <td><font color="blue">As of June </font>30, 2004, the AVI shares had     <font color="blue">been trading</font> below our <font color="blue">original cost basis</font> for more <font color="blue">than six months</font></td>
    </tr>
    <tr>
      <td><font color="blue">Since     </font>there was no <font color="blue">compelling evidence</font> to the contrary, we recorded the <font color="blue">impairment</font>     charge of dlra7dtta9 million in our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The amount of the     charge was <font color="blue">based on</font> the <font color="blue">difference between</font> the <font color="blue">market price</font> of the shares as     of June 30, 2004 and our <font color="blue">adjusted cost basis</font></td>
    </tr>
    <tr>
      <td>The public <font color="blue">trading price</font>s of     the AVI shares have fluctuated <font color="blue">significant</font>ly since we <font color="blue">purchased them</font> and     could  continue to do so</td>
    </tr>
    <tr>
      <td>If the public <font color="blue">trading price</font>s of these shares     continue to trade below their new       31     ______________________________________________________________________       cost basis in future periods, we may incur <font color="blue">additional</font> <font color="blue">impairment</font> charges     relating  to this <font color="blue">investment</font>, which in turn will affect our results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, in <font color="blue">connection</font> with the <font color="blue">restructuring</font> of our <font color="blue">February Notes </font>and     the  issuance  of the June Notes, we issued three-year warrants to the     <font color="blue">June Note  </font>holders  exercisable into 2cmam634cmam211 of our AVI shares at an     <font color="blue">exercise price</font> of dlra5dtta00 per share, and we pledged the AVI shares to secure     our <font color="blue">obligation under</font> the June Notes</td>
    </tr>
    <tr>
      <td>These warrants expire on <font color="blue">December </font>31,     2006</td>
    </tr>
    <tr>
      <td>Product Development and Regulatory Risks       Before we can seek <font color="blue"><font color="blue">regulatory</font> approval</font> of any of our <font color="blue"><font color="blue">product candidate</font>s</font>, we     must  complete <font color="blue"><font color="blue">clinical trial</font>s</font>, which are expensive and have uncertain     outcomes</td>
    </tr>
    <tr>
      <td>Most of our products are in the <font color="blue">development</font>al stage and, prior to their     sale, will require <font color="blue"><font color="blue">regulatory</font> approval</font> and the <font color="blue">commitment</font> of substantial     resources</td>
    </tr>
    <tr>
      <td>Before obtaining <font color="blue"><font color="blue">regulatory</font> approval</font>s for the <font color="blue">commercial sale</font> of     any of our <font color="blue"><font color="blue">product candidate</font>s</font>, we must demonstrate through pre-clinical     testing  and  <font color="blue"><font color="blue">clinical trial</font>s</font> that our <font color="blue"><font color="blue">product candidate</font>s</font> are safe and     <font color="blue">effective</font> for use in humans</td>
    </tr>
    <tr>
      <td>We  have a portfolio of <font color="blue">cancer drugs</font> in <font color="blue">various stages</font> of <font color="blue">development</font>,     including Nipent (for <font color="blue">indications</font> other than <font color="blue">hairy cell leukemia</font>, Phase IV),     Partaject busulfan (Phase I/II), <font color="blue">Orathecin </font><font color="blue">capsules as</font> a <font color="blue">combination</font> therapy     (Phase II), and we have been conducting pre-clinical studies <font color="blue">for VEGF </font>and     Cremophor-free <font color="blue">paclitaxel</font></td>
    </tr>
    <tr>
      <td>In addition, we expect to <font color="blue">commence new clinical</font>     trials  from time to time in the course of our business as our product     <font color="blue">development</font> work continues</td>
    </tr>
    <tr>
      <td><font color="blue">Conducting </font><font color="blue"><font color="blue">clinical trial</font>s</font> is a lengthy, time     consuming and <font color="blue">expensive process</font> and the results are <font color="blue">inherently uncertain</font></td>
    </tr>
    <tr>
      <td>We     have incurred and <font color="blue">will continue</font> to incur substantial expense for, and we     have devoted and expect to continue to devote a <font color="blue">significant</font> amount of time     to,  pre-clinical  testing  and  clinical  trials</td>
    </tr>
    <tr>
      <td>However, <font color="blue">regulatory</font>     <font color="blue"><font color="blue">authorities</font> may</font> not <font color="blue">permit us</font> to undertake any <font color="blue">additional</font> <font color="blue"><font color="blue">clinical trial</font>s</font>     for  our <font color="blue"><font color="blue">product candidate</font>s</font></td>
    </tr>
    <tr>
      <td>If we are unable to complete our clinical     trials, our business will be <font color="blue">severely harmed</font> and the price of our stock will     <font color="blue">likely decline</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">ongoing research</font> and pre-clinical projects that may lead to product     <font color="blue">candidates</font>, but we have not begun <font color="blue"><font color="blue">clinical trial</font>s</font> for these projects</td>
    </tr>
    <tr>
      <td>If we     do not <font color="blue">successfully</font> complete our pre-<font color="blue"><font color="blue">clinical trial</font>s</font>, we could not commence     <font color="blue"><font color="blue">clinical trial</font>s</font> as planned</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">clinical trial</font>s</font> may be delayed or terminated, <font color="blue">which would</font> prevent us     from seeking <font color="blue">necessary</font> <font color="blue"><font color="blue">regulatory</font> approval</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">Completion </font>of <font color="blue"><font color="blue">clinical trial</font>s</font> may take several years or more</td>
    </tr>
    <tr>
      <td>The length of     a <font color="blue">clinical trial</font> varies <font color="blue">substantially</font> according to the type, <font color="blue">complexity</font>,     novelty and <font color="blue">intended use</font> of the <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>For example, our three     <font color="blue">Phase III </font><font color="blue">Orathecin </font><font color="blue"><font color="blue">clinical trial</font>s</font> lasted from 1998 through the end of     2003</td>
    </tr>
    <tr>
      <td>The length of time and <font color="blue">complexity</font> of these studies make statistical     <font color="blue">analysis <font color="blue">difficult</font></font> and <font color="blue"><font color="blue">regulatory</font> approval</font> unpredictable</td>
    </tr>
    <tr>
      <td>The <font color="blue">commencement</font>     and  rate  of <font color="blue">completion</font> of our <font color="blue"><font color="blue">clinical trial</font>s</font> may be <font color="blue">delayed by</font> many     factors, including:       ·       in<font color="blue">effective</font>ness of the <font color="blue">study compound</font>, or <font color="blue">perceptions by physicians</font>     that the compound is not <font color="blue">effective</font> for a <font color="blue">particular indication</font>;       ·       <font color="blue">inability</font> to <font color="blue"><font color="blue">manufacture</font> sufficient quantities</font> of compounds for use     in <font color="blue"><font color="blue">clinical trial</font>s</font>;       ·       <font color="blue">inability</font> to obtain FDA approval of our <font color="blue"><font color="blue">clinical trial</font> protocols</font>;       ·       <font color="blue">slower than</font> expected rate of <font color="blue">patient recruitment</font>;       ·       <font color="blue">inability</font> to <font color="blue">adequately follow patients</font> after treatment;       ·       <font color="blue"><font color="blue">difficult</font>y</font> in <font color="blue">managing <font color="blue">multiple clinical</font> sites</font>;       32     ______________________________________________________________________       ·       <font color="blue">unforeseen safety issues</font>;       ·       lack of <font color="blue">efficacy demonstrated during</font> the <font color="blue"><font color="blue">clinical trial</font>s</font>; or       ·       <font color="blue">government</font> or <font color="blue">regulatory</font> delays</td>
    </tr>
    <tr>
      <td>If  we  are unable to achieve a satisfactory rate of <font color="blue">completion</font> of our     <font color="blue"><font color="blue">clinical trial</font>s</font>, our business will be <font color="blue">significant</font>ly harmed</td>
    </tr>
    <tr>
      <td>We may be required to suspend, repeat or terminate our <font color="blue"><font color="blue">clinical trial</font>s</font> if     they are not conducted in <font color="blue">compliance with</font> <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Our  clinical  trials  must  be conducted in <font color="blue">accordance with</font> the FDA’s     <font color="blue">regulations</font>  and  are  subject  to <font color="blue">continuous oversight by</font> the FDA and     <font color="blue">institutional</font> review boards at the medical <font color="blue">institutions</font> where the clinical     trials are conducted</td>
    </tr>
    <tr>
      <td>We <font color="blue">outsource certain aspects</font> of our research and     <font color="blue"><font color="blue">development</font> <font color="blue">activities</font></font> to <font color="blue">contract research organizations</font> (“CROs”)</td>
    </tr>
    <tr>
      <td>We have     <font color="blue">agreement</font>s with these CROs for certain of our clinical programs</td>
    </tr>
    <tr>
      <td>We and our     CROs are required to <font color="blue">comply with</font> GCPs, <font color="blue">regulations</font> and <font color="blue"><font color="blue">guidelines</font> enforced</font>     by the FDA for all of our products in clinical <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>The FDA enforces     GCPs   through  periodic  <font color="blue">inspections</font>  of  study  sponsors,  principal     <font color="blue">investigators</font>,  and <font color="blue">study sites</font></td>
    </tr>
    <tr>
      <td>If our CROs or we fail to <font color="blue">comply with</font>     applicable GCPs, the clinical data generated in our studies may be deemed     unreliable <font color="blue">and the FDA </font>may require us to perform <font color="blue">additional</font> studies before     approving  our  <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue"><font color="blue">clinical trial</font>s</font> must be     conducted with <font color="blue"><font color="blue">product candidate</font>s</font> produced <font color="blue">under current</font> GMPs, and may     require a large number of test subjects</td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue">comply with</font> these     <font color="blue">regulations</font> may require us to repeat clinical studies, <font color="blue">which would</font> delay the     <font color="blue"><font color="blue">regulatory</font> approval</font> process</td>
    </tr>
    <tr>
      <td>We may be required to suspend, repeat or terminate our <font color="blue"><font color="blue">clinical trial</font>s</font> if     <font color="blue">later trial</font> results fail to <font color="blue">demonstrate safety</font> and efficacy, or if the     results are negative, <font color="blue">inconclusive</font> or if they fail to <font color="blue">demonstrate safety</font> or     efficacy</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">clinical trial</font>s</font> may be <font color="blue">suspended at</font> any time if we or the FDA believe     the <font color="blue">patients participating</font> in our studies are exposed to unacceptable health     risks or if we or the FDA <font color="blue">find deficiencies</font> in the conduct of these trials</td>
    </tr>
    <tr>
      <td>Adverse <font color="blue">medical events during</font> a <font color="blue">clinical trial</font> could cause us to terminate     or repeat a <font color="blue">clinical trial</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may encounter</font> other problems and failures in our studies that would cause     us or the FDA to delay or suspend the studies</td>
    </tr>
    <tr>
      <td>Even if we achieve positive     interim results in <font color="blue"><font color="blue">clinical trial</font>s</font>, these results do not <font color="blue">necessarily predict</font>     final results, and acceptable results in <font color="blue">early trials may</font> not be repeated in     <font color="blue">later trial</font>s</td>
    </tr>
    <tr>
      <td>A number of companies in the <font color="blue"><font color="blue">pharmaceutical</font> industry</font> have     suffered  <font color="blue">significant</font> setbacks in advanced <font color="blue"><font color="blue">clinical trial</font>s</font>, even after     achieving promising results in <font color="blue">earlier trials</font></td>
    </tr>
    <tr>
      <td>Negative or <font color="blue">inconclusive</font> results during a <font color="blue">clinical trial</font> could cause us to     terminate or repeat a <font color="blue">clinical trial</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">potential failure</font>s would delay</font>     <font color="blue">development</font> of our <font color="blue"><font color="blue">product candidate</font>s</font>, hinder our ability to conduct related     pre-clinical testing and <font color="blue"><font color="blue">clinical trial</font>s</font> and <font color="blue">further delay</font> the <font color="blue">commencement</font>     of the <font color="blue"><font color="blue">regulatory</font> approval</font> process</td>
    </tr>
    <tr>
      <td>Further, the failures or perceived     failures in our <font color="blue"><font color="blue">clinical trial</font>s</font> would delay our product <font color="blue">development</font> and the     <font color="blue">regulatory</font>  approval  process,  damage our business prospects, make it     <font color="blue">difficult</font> for us to <font color="blue">establish <font color="blue">collaboration</font></font> and <font color="blue">partnership <font color="blue">relationships</font></font>     and  <font color="blue">negatively</font>  affect our reputation and <font color="blue"><font color="blue">competitive</font> position</font> in the     <font color="blue">pharmaceutical</font>  industry</td>
    </tr>
    <tr>
      <td>Finally, if we are required to conduct other     <font color="blue"><font color="blue">clinical trial</font>s</font> for the <font color="blue"><font color="blue">product candidate</font>s</font>, the <font color="blue">additional</font> trials would     require substantial funding and time, and we may be unable to obtain funding     to conduct such <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Our failure to obtain <font color="blue"><font color="blue">regulatory</font> approval</font>s to market our <font color="blue"><font color="blue">product candidate</font>s</font>     in <font color="blue">foreign countries</font> would <font color="blue">adversely</font> affect our anticipated revenues</td>
    </tr>
    <tr>
      <td>Sales of our products in foreign <font color="blue"><font color="blue">jurisdiction</font>s</font> will be subject to separate     <font color="blue">regulatory</font> <font color="blue">requirements</font> and marketing approvals</td>
    </tr>
    <tr>
      <td>Approval in the United     States, or in any <font color="blue">one foreign <font color="blue">jurisdiction</font></font>, does not ensure       33     ______________________________________________________________________       approval  in  any other <font color="blue">jurisdiction</font></td>
    </tr>
    <tr>
      <td>The process of obtaining foreign     <font color="blue">approvals may</font> result in <font color="blue">significant</font> delays, <font color="blue">difficult</font>ies and expenses for     us, and may require <font color="blue">additional</font> <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">applied through</font> our     subsidiary  <font color="blue">EuroGen  </font>for  <font color="blue">regulatory</font>  approval to market mitomycin and     <font color="blue">paclitaxel</font> <font color="blue">in the United Kingdom </font>and in other <font color="blue">countries within</font> the European     Union</td>
    </tr>
    <tr>
      <td>Although many of the <font color="blue">regulations</font> applicable to our products in these     <font color="blue">foreign countries</font> are similar to those <font color="blue">promulgated by</font> the FDA, many of these     <font color="blue">requirements</font> also vary widely from country to country, <font color="blue">which could</font> delay the     <font color="blue">introduction</font> of our products in those countries</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font>     these <font color="blue">regulatory</font> <font color="blue">requirements</font> or to obtain required <font color="blue">approvals would impair</font>     our ability to <font color="blue">commercialize</font> our products in <font color="blue">foreign markets</font></td>
    </tr>
    <tr>
      <td>Nipent is <font color="blue">currently sold</font> in Europe, and in early 2004 we acquired the rights     to market Nipent <font color="blue">there directly</font></td>
    </tr>
    <tr>
      <td>We plan to directly <font color="blue">commercialize</font> and     market Nipent in Europe during 2006</td>
    </tr>
    <tr>
      <td>However, our <font color="blue">revenue from</font> sales of     Nipent in Europe is currently less than 10prca of our <font color="blue">total sales</font>, and there is     no  guarantee  that our <font color="blue">marketing efforts will</font> result in <font color="blue">significant</font>ly     <font color="blue">increased revenues</font></td>
    </tr>
    <tr>
      <td>Our strategy is to obtain <font color="blue"><font color="blue">regulatory</font> approval</font>s to sell     our  products  in Europe and elsewhere, and we intend to <font color="blue">contract with</font>     third-party licensees or <font color="blue">distributors</font> for sales outside <font color="blue">the <font color="blue">United States</font></font></td>
    </tr>
    <tr>
      <td>Delays in obtaining <font color="blue"><font color="blue">regulatory</font> approval</font> from foreign <font color="blue"><font color="blue">jurisdiction</font>s</font> will     impair the <font color="blue">commercialization</font> of our products and would delay anticipated     revenues</td>
    </tr>
    <tr>
      <td>Even if we obtain <font color="blue"><font color="blue">regulatory</font> approval</font>, we <font color="blue">will continue</font> to be subject to     extensive <font color="blue">government</font> regulation that may cause us to delay the <font color="blue">introduction</font>     of our products or withdraw our <font color="blue">products from</font> the market</td>
    </tr>
    <tr>
      <td>Even if <font color="blue"><font color="blue">regulatory</font> approval</font> of our products is obtained, <font color="blue">later discovery</font> of     <font color="blue">previously</font>  unknown  <font color="blue">problems may</font> result in <font color="blue"><font color="blue">restriction</font>s</font> of a product,     including withdrawal of that <font color="blue">product from</font> the market</td>
    </tr>
    <tr>
      <td>Further, <font color="blue">government</font>al     <font color="blue">approval may</font> subject us to ongoing <font color="blue">requirements</font> for post-marketing studies</td>
    </tr>
    <tr>
      <td>For example, despite receipt of <font color="blue">government</font>al approval, the <font color="blue">facilities</font> of our     third-party <font color="blue"><font color="blue">manufacture</font>rs</font> are still subject to unannounced <font color="blue">inspections</font> by     the FDA and must continue to <font color="blue">comply with</font> GMPs and other <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">regulations</font> govern all areas of production, record keeping, personnel and     <font color="blue">quality control</font></td>
    </tr>
    <tr>
      <td>In the past, our third-party <font color="blue"><font color="blue">manufacture</font>rs</font> have experienced     delayed FDA approval, which <font color="blue">adversely</font> affected our ability to supply <font color="blue">Nipent     </font>in 2002</td>
    </tr>
    <tr>
      <td>If we or our third-party <font color="blue"><font color="blue">manufacture</font>rs</font> fail to <font color="blue">comply with</font> any of     the <font color="blue">manufacturing</font> <font color="blue">regulations</font>, we may be subject to, among other things,     product seizures, recalls, fines, injunctions, <font color="blue">suspensions</font> or <font color="blue">revocations</font> of     <font color="blue">marketing licenses</font>, operating <font color="blue"><font color="blue">restriction</font>s</font> and <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td><font color="blue">Physicians  </font>may  prescribe  drugs for uses that are not described in a     product’s labeling that <font color="blue">differ from</font> those <font color="blue">tested by us</font> and <font color="blue">approved by</font> the     FDA While such “off-label” uses are common <font color="blue">and the FDA </font>does not regulate     physicians’ choice of <font color="blue">treatments</font>, the FDA does restrict a <font color="blue">manufacture</font>r’s     <font color="blue">communications on</font> the subject of off-label use</td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font><font color="blue">cannot actively</font>     promote FDA-<font color="blue">approved drugs</font> for off-label uses, but they <font color="blue">may <font color="blue">disseminate</font></font> to     <font color="blue">physicians articles published</font> in peer-reviewed journals</td>
    </tr>
    <tr>
      <td>To the extent     allowed by law, we intend to <font color="blue">disseminate</font> peer-reviewed articles on our     products to our physician customers</td>
    </tr>
    <tr>
      <td>If, however, our <font color="blue">promotional <font color="blue">activities</font></font>     fail to <font color="blue">comply with</font> the FDA’s <font color="blue">regulations</font> or <font color="blue">guidelines</font>, we may be subject     to <font color="blue"><font color="blue">enforcement</font> action by</font> the FDA For example, in June 2005 we received a     <font color="blue">Warning Letter </font>from the FDA regarding <font color="blue">certain promotional materials</font> we     <font color="blue">disseminate</font>d for Nipent</td>
    </tr>
    <tr>
      <td>The FDA asserted that these materials were false or     misleading because they failed to present any risk information, contained an     <font color="blue">unsubstantiated</font> claim regarding the mechanism of action, and overstated the     safety and efficacy of the drug</td>
    </tr>
    <tr>
      <td>In response, we recalled these materials     from the field and <font color="blue">commenced modifying</font> our <font color="blue">internal procedures</font> to ensure     that future Nipent <font color="blue">marketing materials</font> and <font color="blue">promotional <font color="blue">activities</font></font> meet     <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>We will also be sending a <font color="blue">corrective communication</font>     to physicians who received the violative Nipent materials</td>
    </tr>
    <tr>
      <td>The FDA has     accepted our remedial actions, nonetheless, any further <font color="blue">Warning Letters </font>or     <font color="blue">enforcement</font> actions by the FDA <font color="blue">could harm</font> our reputation in the market,     result  in <font color="blue">significant</font> fines or have other affects that <font color="blue">could harm</font> our     business</td>
    </tr>
    <tr>
      <td>34     ______________________________________________________________________       The <font color="blue">continuing efforts</font> of <font color="blue">government</font> and third-party payers to contain or     reduce the costs of healthcare may <font color="blue">adversely</font> affect our revenues</td>
    </tr>
    <tr>
      <td>Sales of our products depend in part upon the <font color="blue">availability</font> of <font color="blue">reimbursement</font>     from third-party payers, such as health <font color="blue">administration</font> <font color="blue">authorities</font> like     Medicare/Medicaid, <font color="blue">managed care providers</font> and <font color="blue">private health insurers</font></td>
    </tr>
    <tr>
      <td>Third-party payers are <font color="blue">increasingly challenging</font> the price and examining the     cost <font color="blue">effective</font>ness of <font color="blue">medical products</font> and services, which may <font color="blue">effective</font>ly     limit physicians’ ability to select products and procedures</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">significant</font> un<font color="blue">certainty</font> exists as to the <font color="blue">reimbursement</font> status     of <font color="blue">newly approved healthcare products</font></td>
    </tr>
    <tr>
      <td>For example, currently Medicare does     not reimburse self-<font color="blue">administered</font> products, <font color="blue">which could</font> cover some of our     <font color="blue"><font color="blue">product candidate</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Adequate </font>third-party <font color="blue">reimbursement</font> may not be available     to <font color="blue">enable us</font> to maintain <font color="blue">price levels sufficient</font> to realize an <font color="blue">appropriate</font>     return on our <font color="blue">investment</font> in a <font color="blue">particular product</font></td>
    </tr>
    <tr>
      <td>In addition, we believe     <font color="blue">government</font> agencies <font color="blue">will continue</font> to propose and <font color="blue">pass legislation designed</font>     to reduce the cost of healthcare, <font color="blue">which could</font> further limit <font color="blue">reimbursement</font>     for  <font color="blue">pharmaceutical</font>s, and we anticipate that there <font color="blue">will continue</font> to be     proposals in the <font color="blue"><font color="blue">United States</font> </font>to implement <font color="blue">government</font> control over the     pricing or <font color="blue">profitability</font> of <font color="blue">prescription</font> <font color="blue">pharmaceutical</font>s, as is currently     the case in many <font color="blue">foreign markets</font></td>
    </tr>
    <tr>
      <td>If our current and <font color="blue">proposed products</font> are     not considered cost-<font color="blue">effective</font>, <font color="blue">reimbursement</font> to the <font color="blue">consumer may</font> not be     available or be sufficient to allow us to <font color="blue">sell products on</font> a <font color="blue">competitive</font>     basis</td>
    </tr>
    <tr>
      <td>The failure of the <font color="blue">government</font> and third-party payers to provide     <font color="blue">adequate coverage</font> and <font color="blue">reimbursement</font> rates for our <font color="blue"><font color="blue">product candidate</font>s</font> could     <font color="blue">adversely</font> affect the <font color="blue">market <font color="blue">acceptance</font></font> of our products, our <font color="blue">competitive</font>     position and our <font color="blue">financial performance</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">comply with</font> <font color="blue">environmental</font> laws and <font color="blue">regulations</font>, our     business may be harmed</td>
    </tr>
    <tr>
      <td>We are subject to federal, state and <font color="blue">local laws</font> and <font color="blue">regulations</font> governing     the use, <font color="blue">manufacture</font>, storage, handling and disposal of <font color="blue">hazardous materials</font>     and <font color="blue">waste products</font></td>
    </tr>
    <tr>
      <td>We currently maintain a supply of bio<font color="blue">hazardous materials</font>     at our <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>We believe our <font color="blue">safety procedures</font> for these materials     <font color="blue">comply with</font> all <font color="blue">applicable <font color="blue">environmental</font> laws</font> and <font color="blue">regulations</font>, and we carry     <font color="blue">insurance coverage</font> we believe is adequate for the size of our business</td>
    </tr>
    <tr>
      <td>However, we <font color="blue">cannot entirely eliminate</font> the risk of <font color="blue"><font color="blue">accident</font>al contamination</font>     or <font color="blue">injury from</font> these materials</td>
    </tr>
    <tr>
      <td>If an <font color="blue">accident</font> or <font color="blue">environmental</font> discharge     occurs, we could be held liable for any resulting damages, <font color="blue">which could</font>     exceed our <font color="blue">insurance coverage</font> and <font color="blue">financial resources</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">currently outsource certain</font> of our research and <font color="blue">development</font> programs     involving the <font color="blue">controlled use</font> of bio<font color="blue">hazardous materials</font></td>
    </tr>
    <tr>
      <td>We believe our     <font color="blue">collaborators</font> have in place <font color="blue">safety procedures</font> for these materials that     <font color="blue">comply with</font> <font color="blue">government</font>al standards</td>
    </tr>
    <tr>
      <td>Nevertheless, if an <font color="blue">accident</font> does occur,     our research and product <font color="blue">development</font> will be <font color="blue">negatively</font> affected</td>
    </tr>
    <tr>
      <td><font color="blue">Additional Risks Associated </font>with Our Business       We recently announced our intent to acquire Montigen Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>This <font color="blue"><font color="blue">transaction</font> <font color="blue">could disrupt</font></font> our business and harm our <font color="blue">financial condition</font>     if we are not able to <font color="blue">successfully</font> close the <font color="blue">acquisition</font> or <font color="blue">successfully</font>     integrate Montigen’s business and <font color="blue"><font color="blue">technology</font> into ours</font>, and if we do close     the  <font color="blue">acquisition</font>,  the  expected  benefits  of the <font color="blue">combination</font> may not     <font color="blue">materialize</font></td>
    </tr>
    <tr>
      <td>We   recently   entered   into   an   <font color="blue">agreement</font>  to  acquire  Montigen     Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>for cash and shares of our <font color="blue">common stock valued at</font>     <font color="blue">approximately</font> dlra40dtta0 million, including dlra22dtta0 million contingent upon the     <font color="blue">achievement</font> of specific <font color="blue">regulatory</font> <font color="blue">milestones</font></td>
    </tr>
    <tr>
      <td>We have, and <font color="blue">will continue</font>     to, expend <font color="blue">significant</font> efforts on closing this <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td>Such efforts are     costly  from  both a personnel and financial perspective, distract key     personnel  from  their  ordinary  <font color="blue">responsibilities</font>, and may or may not     ultimately result in the <font color="blue">consummation</font> of the <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>The closing of the     <font color="blue">transaction</font> is subject to <font color="blue">numerous variables</font>, some of which are beyond our     control</td>
    </tr>
    <tr>
      <td>There  can be no assurance that we will be able to close the     Montigen <font color="blue">acquisition</font>, and       35     ______________________________________________________________________       failure to do so may <font color="blue">negatively</font> affect our financial results, employee and     <font color="blue">investor confidence</font>, and ultimately our stock price</td>
    </tr>
    <tr>
      <td>The  Montigen  <font color="blue">acquisition</font> involves <font color="blue">numerous risks</font>, including problems     combining the purchased <font color="blue">operations</font> or <font color="blue">technologies</font>, unanticipated costs and     diversion of <font color="blue">management</font>’s attention from our core business</td>
    </tr>
    <tr>
      <td>In addition, we     may  have  to  <font color="blue">restructure aspects</font> of our business in order to achieve     anticipated synergies</td>
    </tr>
    <tr>
      <td>There can be no assurance that we will be able to     <font color="blue">successfully</font> integrate Montigen and its <font color="blue">technology</font> and personnel into our     business</td>
    </tr>
    <tr>
      <td>The failure to <font color="blue">effective</font>ly manage the <font color="blue">acquisition</font> and <font color="blue">integration</font>     of Montigen <font color="blue">could disrupt</font> our business and harm our financial results</td>
    </tr>
    <tr>
      <td>Further,  if  consummated,  the  <font color="blue">transaction</font>  <font color="blue">will dilute</font> our existing     <font color="blue">stockholders</font>’ percentage ownership and decrease our <font color="blue">cash position</font></td>
    </tr>
    <tr>
      <td>If the third-party <font color="blue"><font color="blue">manufacture</font>rs</font> upon whom we rely fail to produce our     products in the volumes that we require on a <font color="blue">timely basis</font>, or fail to comply     with stringent <font color="blue">regulations</font> applicable to <font color="blue">pharmaceutical</font> drug <font color="blue"><font color="blue">manufacture</font>rs</font>,     we <font color="blue">may face delays</font> in the delivery of, or be unable to meet demand for, our     products</td>
    </tr>
    <tr>
      <td>Because we have no <font color="blue">manufacturing</font> <font color="blue">facilities</font>, we <font color="blue">rely on <font color="blue">third parties</font></font> for     <font color="blue"><font color="blue">manufacturing</font> <font color="blue">activities</font></font> related to all of our products</td>
    </tr>
    <tr>
      <td>As we develop new     products and <font color="blue">increase sales</font> of our <font color="blue">existing products</font>, we <font color="blue">must establish</font> and     maintain <font color="blue"><font color="blue">relationships</font> with</font> <font color="blue"><font color="blue">manufacture</font>rs</font> to produce and <font color="blue">package sufficient</font>     supplies of our finished <font color="blue">pharmaceutical</font> products, including Nipent</td>
    </tr>
    <tr>
      <td><font color="blue">Reliance     </font><font color="blue">on <font color="blue">third party</font> <font color="blue">manufacturing</font> presents</font> the <font color="blue">following risks</font>:       ·        delays in scale-up to quantities needed for <font color="blue">multiple clinical</font>     trials, or failure to (a) <font color="blue"><font color="blue">manufacture</font> such quantities</font> to our <font color="blue">specifications</font>     or (b) deliver <font color="blue">such quantities on</font> the dates we require, <font color="blue">which could</font> cause     delay  or  suspension  of  <font color="blue"><font color="blue">clinical trial</font>s</font>, <font color="blue">regulatory</font> submissions and     <font color="blue">commercialization</font> of our products;       ·       <font color="blue">inability</font> to fulfill our commercial needs if <font color="blue">market demand</font> for our     products  increases  suddenly,  which  would  require  us  to seek new     <font color="blue"><font color="blue">manufacturing</font> arrangements</font> and may result in substantial delays in meeting     <font color="blue">market demand</font>;       ·       potential <font color="blue">relinquish</font>ment or sharing of <font color="blue"><font color="blue">intellectual</font> <font color="blue">property rights</font></font>     to any <font color="blue">improvements</font> in the <font color="blue"><font color="blue">manufacturing</font> processes</font> or <font color="blue">new <font color="blue">manufacturing</font></font>     processes for our products; and       ·       unannounced ongoing <font color="blue">inspections</font> by the FDA and <font color="blue">corresponding</font> state     agencies for <font color="blue">compliance with</font> GMPs, <font color="blue">regulations</font> and <font color="blue">foreign standards</font>, and     failure to <font color="blue">comply with</font> any of these <font color="blue">regulations</font> and <font color="blue">standards may</font> subject us     to, among other things, product seizures, recalls, fines, injunctions,     <font color="blue">suspensions</font> or <font color="blue">revocations</font> of <font color="blue">marketing licenses</font>, operating <font color="blue"><font color="blue">restriction</font>s</font> and     <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td>Any of these <font color="blue">factors could</font> delay <font color="blue"><font color="blue">clinical trial</font>s</font> or <font color="blue">commercialization</font> of our     <font color="blue"><font color="blue">product candidate</font>s</font> under <font color="blue">development</font>, interfere with current sales and     entail higher costs</td>
    </tr>
    <tr>
      <td>For example, a <font color="blue">failed production batch</font> of Nipent in the     <font color="blue">second quarter</font> of 2003 affected our ability to supply Nipent and <font color="blue">adversely</font>     affected our sales</td>
    </tr>
    <tr>
      <td><font color="blue">Currently </font>we store the majority of the unpurified, bulk form of Nipent at     the <font color="blue">manufacture</font>r’s location</td>
    </tr>
    <tr>
      <td>Improper storage, fire, natural disaster, theft     or other <font color="blue">conditions at</font> this <font color="blue">location may lead</font> to the loss or <font color="blue">destruction</font> of     the <font color="blue">bulk concentrate</font></td>
    </tr>
    <tr>
      <td>Even if the <font color="blue">manufacture</font>r’s and our <font color="blue">insurance coverage</font>     is adequate, such event would inevitably cause delays in <font color="blue">distribution</font> and     sales of our products and harm our operating results</td>
    </tr>
    <tr>
      <td>Our business may be harmed if the <font color="blue">manufacture</font> of our products is <font color="blue">interrupted</font>     or <font color="blue">discontinued</font></td>
    </tr>
    <tr>
      <td>We  may  be  unable to maintain our <font color="blue"><font color="blue">relationships</font> with</font> our third-party     <font color="blue"><font color="blue">manufacture</font>rs</font></td>
    </tr>
    <tr>
      <td>If we need to replace or seek new <font color="blue"><font color="blue">manufacturing</font> arrangements</font>,     we  may  have  <font color="blue"><font color="blue">difficult</font>y</font> locating and <font color="blue">entering into arrangements with</font>     qualified contract <font color="blue"><font color="blue">manufacture</font>rs</font> on acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>We are     aware of only a       36     ______________________________________________________________________       limited number of <font color="blue">companies on</font> a <font color="blue">worldwide basis</font> who operate <font color="blue">manufacturing</font>     <font color="blue">facilities</font> in which our products can be <font color="blue">manufacture</font>d to our <font color="blue">specifications</font>     and in <font color="blue">compliance with</font> GMPs</td>
    </tr>
    <tr>
      <td>It could take <font color="blue">several months</font>, or <font color="blue">significant</font>ly     longer, for a new contract <font color="blue">manufacturing</font> facility to obtain FDA approval and     to develop <font color="blue">substantially</font> equivalent processes for the production of our     products</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">contract with</font> any of these <font color="blue">companies on</font>     acceptable  terms,  if  at all</td>
    </tr>
    <tr>
      <td>For example, the company that had been     purifying  Nipent filed for <font color="blue">reorganization under</font> Chapter 11 and ceased     <font color="blue">operations</font> in late 2004</td>
    </tr>
    <tr>
      <td>We have <font color="blue">contracted with</font> another <font color="blue">manufacture</font>r for     the <font color="blue">purification</font> of Nipent</td>
    </tr>
    <tr>
      <td>If the new <font color="blue">manufacture</font>r is not qualified by the     FDA or if the new <font color="blue">manufacture</font>r should go out of business, we may not have     adequate inventory levels to sustain our business while we identify and     <font color="blue">contract with</font> another <font color="blue">manufacture</font>r for the <font color="blue">purification</font> of Nipent</td>
    </tr>
    <tr>
      <td>If our <font color="blue">suppliers cannot provide</font> the <font color="blue">components</font> we require, our <font color="blue">product sales</font>     and <font color="blue">revenue could</font> be harmed</td>
    </tr>
    <tr>
      <td>We rely on third-party suppliers to <font color="blue">provide us with</font> numerous <font color="blue">components</font> used     in  our  products  under  <font color="blue">development</font>, including Orathecin</td>
    </tr>
    <tr>
      <td>Relying on     third-party  suppliers  makes  us vulnerable to component failures and     <font color="blue">interruptions</font> in supply, either of <font color="blue">which could</font> impair our ability to conduct     <font color="blue"><font color="blue">clinical trial</font>s</font> or to ship our products to our <font color="blue">customers on</font> a <font color="blue">timely basis</font></td>
    </tr>
    <tr>
      <td>Using third-party suppliers makes it <font color="blue">difficult</font> and <font color="blue">sometimes impossible</font> for     us to maintain <font color="blue">quality control</font>, manage inventory and <font color="blue">production schedules</font>     and <font color="blue">control production costs</font></td>
    </tr>
    <tr>
      <td>Vendor <font color="blue">lead times</font> to <font color="blue">supply us with ordered</font>     <font color="blue">components</font> vary <font color="blue">significant</font>ly and can <font color="blue">exceed six months</font> or more</td>
    </tr>
    <tr>
      <td>Both now     and as we expand our need for <font color="blue">manufacturing</font> capacity, we cannot be sure that     our <font color="blue">suppliers will furnish us with</font> required <font color="blue">components</font> when we need them</td>
    </tr>
    <tr>
      <td>These <font color="blue">factors could</font> make it <font color="blue">difficult</font> for us to <font color="blue">effective</font>ly and <font color="blue">efficiently</font>     <font color="blue">manufacture</font> our products, and could <font color="blue">adversely</font> impact our <font color="blue"><font color="blue">clinical trial</font>s</font>,     product <font color="blue">development</font> and sales of our products</td>
    </tr>
    <tr>
      <td>Some suppliers are our only source for a particular component, which makes     us vulnerable to <font color="blue">cost increases</font> and supply <font color="blue">interruptions</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">generally rely</font>     on  one <font color="blue">manufacture</font>r for <font color="blue">each product</font></td>
    </tr>
    <tr>
      <td>We rely on one <font color="blue">manufacture</font>r for     Nipent, a <font color="blue">sole source supplier</font> for the processing of <font color="blue">pentostatin</font>, which is     used in the <font color="blue">manufacturing</font> of Nipent, and a <font color="blue">sole source supplier</font> for the     ingredient used in the <font color="blue">purification</font> of <font color="blue">pentostatin</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also rely on sole</font>     <font color="blue">source suppliers</font> for <font color="blue">mitomycin products</font> and <font color="blue">Surface Safe</font></td>
    </tr>
    <tr>
      <td>Vendors may decide to limit or <font color="blue">eliminate sales</font> of <font color="blue">certain products</font> to the     <font color="blue">medical industry due</font> to <font color="blue">product <font color="blue">liability</font></font> or other concerns</td>
    </tr>
    <tr>
      <td>For example,     one  component  used  in  the <font color="blue">purification</font> of <font color="blue">pentostatin</font> is no longer     <font color="blue">commercially</font>  available</td>
    </tr>
    <tr>
      <td>In the event one of our <font color="blue">sole source supplier</font>s     decides not to <font color="blue">manufacture</font> the component, goes out of business, or decides     to  cut  off our supply, we may be unable to locate <font color="blue">replacement</font> supply     sources, or the sources that we <font color="blue">may locate may</font> not <font color="blue">provide us with</font> similar     <font color="blue">re<font color="blue">liability</font></font> or pricing and our business <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>If we cannot obtain a     <font color="blue">necessary</font>  component,  we may need to find, test and obtain <font color="blue">regulatory</font>     approval for a <font color="blue">replacement</font> component, produce the component or redesign the     related product, <font color="blue">which would</font> cause <font color="blue">significant</font> delay and <font color="blue">could increase</font> our     <font color="blue">manufacturing</font> costs</td>
    </tr>
    <tr>
      <td>Any of these events could <font color="blue">adversely</font> impact our sales     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have limited sales and <font color="blue">marketing <font color="blue">capabilities</font></font> and may not be able to     <font color="blue">successfully</font> <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>We currently have limited sales and <font color="blue">marketing resources</font></td>
    </tr>
    <tr>
      <td>Although we have 34     sales, marketing and <font color="blue">sales support personnel <font color="blue">focusing on</font></font> the sale of our     products to hospitals and <font color="blue">hospital buying groups</font>, we must expand our sales     and <font color="blue">marketing organization</font> to support <font color="blue">commercialization</font> of our <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>Building up our <font color="blue">sales <font color="blue">capabilities</font> will</font> require <font color="blue">significant</font> expenditures</td>
    </tr>
    <tr>
      <td>We     may  not  succeed  in  expanding and enhancing our sales and marketing     <font color="blue">capabilities</font> or have <font color="blue">sufficient resources</font> to do so</td>
    </tr>
    <tr>
      <td>If we do develop such     <font color="blue">capabilities</font>, we <font color="blue">will <font color="blue">compete with</font></font> other companies that have experienced and     well-funded sales and marketing <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may not be able to upgrade     our in-house sales expertise which may limit our ability to <font color="blue">gain market</font>     <font color="blue">acceptance</font> for our <font color="blue">products worldwide</font> and <font color="blue">generate revenues</font></td>
    </tr>
    <tr>
      <td>If we fail to     establish       37     ______________________________________________________________________       <font color="blue">successful sales</font> and <font color="blue">marketing <font color="blue">capabilities</font></font>, we will not be able to market     or sell our products <font color="blue">effective</font>ly and our business, <font color="blue">financial condition</font> and     results of <font color="blue">operations</font> will be <font color="blue">materially</font> and <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>We intend to <font color="blue"><font color="blue">enter into</font> strategic partnerships</font> for the <font color="blue">commercialization</font> of     our <font color="blue">products outside</font> of <font color="blue">the <font color="blue">United States</font></font></td>
    </tr>
    <tr>
      <td>However, we may not be able to     negotiate acceptable <font color="blue">arrangements with partners</font>, if at all</td>
    </tr>
    <tr>
      <td>Moreover, such     <font color="blue">arrangements may</font> involve sharing of profits from sales, <font color="blue">requirements</font> to     <font color="blue">relinquish</font> certain of our rights to our products or <font color="blue">marketing territories</font>     and <font color="blue">impositions</font> of other <font color="blue">limitations on</font> our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we are not able to maintain and <font color="blue">successfully</font> establish new <font color="blue">collaborative</font>     and <font color="blue">licensing arrangements with <font color="blue">third parties</font></font>, our product <font color="blue">development</font> and     business will be harmed</td>
    </tr>
    <tr>
      <td>Our business model is <font color="blue">based on</font> establishing <font color="blue">collaborative</font> <font color="blue"><font color="blue">relationships</font> with</font>     other  parties  both  to <font color="blue">license compounds upon which</font> our products and     <font color="blue">technologies</font>  are  based  and  to  <font color="blue">manufacture</font>  our  products  or  our     <font color="blue">collaborators</font>’ products</td>
    </tr>
    <tr>
      <td>It is critical that we <font color="blue">gain access</font> to compounds and     <font color="blue">technologies</font> to license for further <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>For example, we licensed     the exclusive worldwide royalty-bearing rights to <font color="blue">Orathecin </font>from The Stehlin     Foundation for Research</td>
    </tr>
    <tr>
      <td>Due to the expense of the <font color="blue">drug approval process</font> we     must have <font color="blue"><font color="blue">relationships</font> with</font> established <font color="blue">pharmaceutical</font> companies to offset     some of our <font color="blue">development</font> costs in exchange for a <font color="blue">combination</font> of <font color="blue">development</font>,     marketing and <font color="blue">distribution</font> rights</td>
    </tr>
    <tr>
      <td>From time to time we <font color="blue"><font color="blue">enter into</font> discussions with various companies</font> regarding     the  <font color="blue">establishment</font>  of <font color="blue">new <font color="blue">collaboration</font>s</font></td>
    </tr>
    <tr>
      <td>If we are not successful in     <font color="blue"><font color="blue">establishing new</font> partners</font> for our <font color="blue"><font color="blue">product candidate</font>s</font>, we may not be able to     pursue further <font color="blue">development</font> of such <font color="blue"><font color="blue">product candidate</font>s</font> and/or may have to     reduce or cease our current <font color="blue">development</font> programs, <font color="blue">which would</font> <font color="blue">materially</font>     harm  our  business</td>
    </tr>
    <tr>
      <td>Even  if  we  are successful in <font color="blue">establishing new</font>     <font color="blue">collaboration</font>s,  they  are subject to <font color="blue">numerous risks</font> and <font color="blue">uncertainties</font>     including:       ·       our ability to negotiate acceptable <font color="blue"><font color="blue">collaborative</font> arrangements</font>;       ·       the <font color="blue">collaboration</font> making <font color="blue">us less attractive</font> to <font color="blue">potential acquirers</font>;       ·        freedom  of  our <font color="blue"><font color="blue">collaborative</font> partners</font> to pursue alternative     <font color="blue">technologies</font> either on their own or <font color="blue">with others</font>, including our <font color="blue">competitors</font>,     for the <font color="blue">diseases targeted by</font> our programs and products;       ·       the <font color="blue">potential failure</font> of our partners to fulfill their <font color="blue">contractual</font>     <font color="blue">obligations</font> or their decision to terminate our <font color="blue">relationships</font>, in <font color="blue">which event</font>     we may be required to seek other partners, or expend substantial resources     to pursue these <font color="blue"><font color="blue">activities</font> independently</font>; and       ·       our ability to manage, interact and coordinate our timelines and     <font color="blue">objectives with</font> our <font color="blue"><font color="blue">collaborative</font> partners</font> may not be successful</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">collaborators</font> may undergo business <font color="blue">combination</font>s, which     could have the effect of making the <font color="blue"><font color="blue">collaboration</font> with</font> <font color="blue">us less attractive</font> to     them for a number of reasons</td>
    </tr>
    <tr>
      <td>For example, if an <font color="blue">existing collaborator</font>     purchases a company that is one of our <font color="blue">competitors</font>, that <font color="blue">company may</font> be less     willing to continue its <font color="blue"><font color="blue">collaboration</font> with</font> us</td>
    </tr>
    <tr>
      <td>A company that has a strategy     of  purchasing  companies with attractive <font color="blue">technologies</font> might have less     incentive  to  <font color="blue">enter into</font> a <font color="blue">collaboration</font> <font color="blue">agreement</font> with us</td>
    </tr>
    <tr>
      <td>Moreover,     <font color="blue">disputes may</font> arise <font color="blue">with respect</font> to the ownership of rights to any <font color="blue">technology</font>     or products developed with any current or <font color="blue">future collaborator</font></td>
    </tr>
    <tr>
      <td><font color="blue">Lengthy     </font>negotiations with potential <font color="blue">collaborators</font> or dis<font color="blue">agreement</font>s between us and     our <font color="blue">collaborators</font> may lead to delays in or <font color="blue">termination</font> of the research,     <font color="blue">development</font> or <font color="blue">commercialization</font> of <font color="blue"><font color="blue">product candidate</font>s</font> or result in time     consuming and <font color="blue">expensive <font color="blue">litigation</font></font> or <font color="blue">arbitration</font></td>
    </tr>
    <tr>
      <td>38     ______________________________________________________________________       Our <font color="blue">collaborative</font> <font color="blue"><font color="blue">relationships</font> with</font> <font color="blue">third parties</font> could cause us to expend     <font color="blue">significant</font>  funds on <font color="blue">development</font> costs with no assurance of financial     return</td>
    </tr>
    <tr>
      <td>From time to time we <font color="blue">enter into</font> <font color="blue">collaborative</font> <font color="blue"><font color="blue">relationships</font> with</font> third     parties to co-develop and <font color="blue">market products</font></td>
    </tr>
    <tr>
      <td>For example, we <font color="blue">entered into</font> an     <font color="blue">agreement</font> with <font color="blue"><font color="blue">Peregrine </font>Pharmaceuticals in February </font>2001, pursuant to which     we licensed a drug-targeting <font color="blue">technology</font> known as Vascular Targeting Agent,     which is a <font color="blue">proprietary</font> platform designed to <font color="blue"><font color="blue">specifically</font> target</font> a tumor’s     blood  supply and <font color="blue">subsequently destroy</font> the <font color="blue">tumor with various attached</font>     <font color="blue">therapeutic</font> agents</td>
    </tr>
    <tr>
      <td>The licensed <font color="blue">technology</font> is <font color="blue">specifically</font> related to VEGF     Under the <font color="blue">agreement</font>, we made an up-front equity <font color="blue">investment</font> <font color="blue">in <font color="blue">Peregrine </font></font>of     dlra600cmam000 and will be obligated to make subsequent <font color="blue">milestone payments</font> that     could ultimately total dlra8dtta25 million</td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">will pay royalties</font> to     <font color="blue">Peregrine </font><font color="blue">based on</font> the <font color="blue">net revenues</font> of any drugs we <font color="blue">commercialize</font> using the     VEGF <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">relationships</font> require substantial financial <font color="blue">commitment</font>s from us, and     at the same time the product <font color="blue">development</font>s are subject to the same <font color="blue">regulatory</font>     <font color="blue">requirements</font>, risks and <font color="blue">uncertainties</font> associated with the <font color="blue">development</font> of our     other  <font color="blue"><font color="blue">product candidate</font>s</font></td>
    </tr>
    <tr>
      <td>The compounds that are the subject of these     <font color="blue"><font color="blue">collaborative</font> <font color="blue">agreement</font>s</font> may prove to be in<font color="blue">effective</font>, may fail to receive     <font color="blue"><font color="blue">regulatory</font> approval</font>s, may be <font color="blue">unprotectable by patents</font> or other <font color="blue">intellectual</font>     <font color="blue">property rights</font>, or may not be otherwise <font color="blue">commercially</font> viable</td>
    </tr>
    <tr>
      <td>If these     <font color="blue">collaborative</font> <font color="blue">relationships</font> are not successful, our product <font color="blue">development</font>s     will be <font color="blue">adversely</font> affected, and our <font color="blue">investment</font>s and <font color="blue">efforts devoted</font> to the     product <font color="blue">development</font>s will be wasted</td>
    </tr>
    <tr>
      <td>Our ability to protect our <font color="blue"><font color="blue">intellectual</font> <font color="blue">property rights</font></font> will be <font color="blue">critically</font>     important to the success of our business, and we may not be able to protect     these rights in the <font color="blue"><font color="blue">United States</font> </font>or abroad</td>
    </tr>
    <tr>
      <td>The success of our <font color="blue">operations</font> depends in part on our ability to obtain     patents, protect <font color="blue">trade secrets</font>, operate <font color="blue">without infringing</font> the <font color="blue">proprietary</font>     rights  of  others  and enforce our <font color="blue">proprietary</font> rights against accused     <font color="blue">infringers</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">actively pursue</font> a policy of <font color="blue">seeking <font color="blue">patent protection</font></font> when applicable for     our  <font color="blue">proprietary</font> products and <font color="blue">technologies</font>, whether they are developed     in-house  or  acquired  from  <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We attempt to protect our     <font color="blue">intellectual</font> property position by filing <font color="blue"><font color="blue">United States</font> </font>and <font color="blue">foreign patent</font>     <font color="blue">application</font>s  related  to  our  <font color="blue">proprietary</font> <font color="blue">technology</font>, <font color="blue">inventions</font> and     <font color="blue">improvements</font> that are important to the <font color="blue">development</font> of our business</td>
    </tr>
    <tr>
      <td>To date,     we have acquired licenses to or <font color="blue">assignments</font> of over 50 US patents covering     <font color="blue">various aspects</font> of our <font color="blue">proprietary</font> drugs and <font color="blue">technologies</font>, including 37     patents for <font color="blue">various aspects</font> of <font color="blue">Orathecin </font>and related products, six patents     under our Nipent product portfolio, although none covers the use of <font color="blue">Nipent     </font>for the treatment of <font color="blue">patients with</font> <font color="blue">hairy cell leukemia</font>, seven patents for     our  <font color="blue">paclitaxel</font>  related  products,  <font color="blue">three patents</font> for Dacogen used in     <font color="blue">combination</font> with an anti-neoplastic agent for the treatment of cancer, and     two patents for our <font color="blue">Surface Safe</font> product</td>
    </tr>
    <tr>
      <td>These issued <font color="blue"><font color="blue">United States</font> </font>patents     will begin to expire in October 2012</td>
    </tr>
    <tr>
      <td>We have <font color="blue">been granted patents</font> and have     received <font color="blue">patent licenses</font> relating to our <font color="blue">proprietary</font> <font color="blue">formulation</font> <font color="blue">technology</font>,     non-oncology and Partaject <font color="blue">technologies</font>, among which at least five patents     are issued or licensed to us</td>
    </tr>
    <tr>
      <td>In addition, we are prosecuting a number of     patent <font color="blue">application</font>s for drug <font color="blue">candidates</font> that we are not actively developing     at this time</td>
    </tr>
    <tr>
      <td>39     ______________________________________________________________________       We also have patents, licenses to patents and pending patent <font color="blue">application</font>s in     Europe,  Australia, Japan, Canada, Mexico and New Zealand, among other     countries</td>
    </tr>
    <tr>
      <td>In addition, we have patent <font color="blue">application</font>s pending in China,     Hungary and Israel</td>
    </tr>
    <tr>
      <td><font color="blue">Limitations </font><font color="blue">on <font color="blue">patent protection</font></font>, and the <font color="blue">differences</font> in     what <font color="blue">constitutes patentable</font> subject matter, may limit the protection we have     <font color="blue">on patents issued</font> or licensed to us in these countries</td>
    </tr>
    <tr>
      <td>In addition, laws of     <font color="blue">foreign countries</font> may not protect our <font color="blue">intellectual</font> property to the same     extent  as  would laws in <font color="blue">the <font color="blue">United States</font></font></td>
    </tr>
    <tr>
      <td>To minimize our costs and     expenses and maintain <font color="blue">effective</font> protection, we focus our <font color="blue">foreign patent</font> and     <font color="blue">licensing <font color="blue">activities</font> primarily</font> in the European Union, Canada and Japan</td>
    </tr>
    <tr>
      <td>In     determining whether or not to <font color="blue">seek <font color="blue">patent protection</font></font> or to license any     patent in a <font color="blue">foreign country</font>, we weigh the <font color="blue">relevant costs</font> and benefits, and     consider, among other things, the <font color="blue">market potential</font> and <font color="blue">profitability</font>, the     scope of <font color="blue"><font color="blue">patent protection</font> afforded by</font> the law of the <font color="blue">jurisdiction</font> and its     <font color="blue">enforceability</font>,  and the nature of terms with any <font color="blue">potential licensees</font></td>
    </tr>
    <tr>
      <td>Failure to obtain adequate <font color="blue">patent protection</font> for our <font color="blue">proprietary</font> drugs and     <font color="blue">technology</font> would impair our ability to be <font color="blue">commercially</font> <font color="blue">competitive</font> in these     markets</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">pharmaceutical</font> industry</font> is <font color="blue">characterized by</font> a large number of patent     <font color="blue">filings involving complex legal</font> and factual questions, and therefore we     cannot  predict  with  <font color="blue">certainty</font>  whether our <font color="blue">patents will</font> be enforced     <font color="blue">effective</font>ly</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may have filed <font color="blue">application</font>s for, or <font color="blue">been issued</font>     <font color="blue">patents on</font>, products or processes that <font color="blue">compete with</font> or are similar to ours</td>
    </tr>
    <tr>
      <td>We  may  not be aware of all of the <font color="blue">patents potentially adverse</font> to our     <font color="blue">interests which may</font> have <font color="blue">been issued</font> to others</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">third parties</font>     may  challenge, invalidate or <font color="blue">circumvent</font> any of our patents</td>
    </tr>
    <tr>
      <td>Thus, any     patents that we own or <font color="blue">license from</font> <font color="blue">third parties</font> may not provide adequate     protection against <font color="blue">competitors</font>, if at all</td>
    </tr>
    <tr>
      <td>Our pending patent <font color="blue">application</font>s     and those we may file in the future, or those we <font color="blue">may <font color="blue">license from</font> third</font>     parties, may not result in patents being <font color="blue">issued with adequate</font> claim scope,     if at all</td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">pursuing <font color="blue">patent protection</font></font> in <font color="blue">appropriate</font> instances, we also     <font color="blue">rely on trade secret protection</font> or <font color="blue">regulatory</font> marketing exclusivity for     unpatented <font color="blue">proprietary</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>However, <font color="blue">trade secrets</font> are <font color="blue">difficult</font> to     protect</td>
    </tr>
    <tr>
      <td>Our <font color="blue">trade secrets</font> or those of our <font color="blue">collaborators</font> may become known or     may be <font color="blue">independently dis<font color="blue">covered by</font> others</font></td>
    </tr>
    <tr>
      <td>In the <font color="blue"><font color="blue">pharmaceutical</font> industry</font> there has been, and we believe that there     <font color="blue">will continue</font> to be, <font color="blue">significant</font> <font color="blue">litigation</font> regarding patent and other     <font color="blue"><font color="blue">intellectual</font> <font color="blue">property rights</font></font></td>
    </tr>
    <tr>
      <td>Claims may be <font color="blue">brought <font color="blue">against us</font></font> in the future     <font color="blue">based on</font> patents held by others</td>
    </tr>
    <tr>
      <td>These <font color="blue">persons could bring legal actions</font>     against  us  claiming  damages and seeking to <font color="blue">enjoin clinical testing</font>,     <font color="blue">manufacturing</font> and marketing of the <font color="blue">affected product</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">become involved</font>     in <font color="blue">litigation</font>, it <font color="blue">could consume</font> a substantial portion of our resources,     <font color="blue">regardless</font> of the outcome of the <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>If a lawsuit <font color="blue">against us</font> is     successful, in addition to any <font color="blue">potential <font color="blue">liability</font></font> for damages, we could be     required  to obtain a license to continue to <font color="blue">manufacture</font> or market the     <font color="blue">affected product</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we <font color="blue">would prevail</font> in a lawsuit     <font color="blue">filed <font color="blue">against us</font></font> or that we could obtain any licenses required under any     <font color="blue">patents on</font> acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">proprietary</font>  products are dependent upon <font color="blue">compliance with</font> numerous     licenses and <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>These licenses and <font color="blue">agreement</font>s require us to make     royalty and other payments, reasonably exploit the underlying <font color="blue">technology</font> of     the <font color="blue">applicable patents</font>, and <font color="blue">comply with</font> <font color="blue">regulatory</font> filings</td>
    </tr>
    <tr>
      <td>If we fail to     <font color="blue">comply with</font> these licenses and <font color="blue">agreement</font>s, we <font color="blue">could lose</font> the underlying     rights to one or more of these potential products, <font color="blue">which would</font> <font color="blue">adversely</font>     affect our product <font color="blue">development</font> and harm our business</td>
    </tr>
    <tr>
      <td>If we fail to compete <font color="blue">effective</font>ly against other <font color="blue">pharmaceutical</font> companies,     our business will suffer</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">pharmaceutical</font> industry</font> in general and the oncology sector in particular     is highly <font color="blue">competitive</font> and subject to <font color="blue">significant</font> and <font color="blue">rapid technological</font>     change</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> and probable <font color="blue">competitors</font> include <font color="blue">companies such as</font>     Aventis SG, Berlex Laboratories, Bristol-Myers Squibb Company, Eli Lilly &amp;     Co, GlaxoSmithKline, Novartis AG, Pfizer, Pharmion Corp</td>
    </tr>
    <tr>
      <td>40     ______________________________________________________________________       Many of our <font color="blue">competitors</font> and research <font color="blue">institutions</font> are <font color="blue">addressing</font> the same     diseases and disease <font color="blue">indications</font> and working on products to treat such     diseases as we are, and have <font color="blue">substantially</font> greater financial, research and     <font color="blue">development</font>, <font color="blue">manufacturing</font> and marketing experience and resources than we     do</td>
    </tr>
    <tr>
      <td>Some of our <font color="blue">competitors</font> have received <font color="blue"><font color="blue">regulatory</font> approval</font> for products,     or are developing or testing <font color="blue"><font color="blue">product candidate</font>s</font> that compete directly with,     our <font color="blue"><font color="blue">product candidate</font>s</font></td>
    </tr>
    <tr>
      <td>For example, while we received <font color="blue">orphan drug status</font>     for <font color="blue">Orathecin </font>and there is currently <font color="blue">no competitor</font> in the <font color="blue">oral delivery</font>     market for the treatment of <font color="blue">pancreatic cancer</font>, there are <font color="blue">approved drugs</font> for     the treatment of <font color="blue">pancreatic cancer</font>, including <font color="blue">gemcitabine by</font> Eli Lilly</td>
    </tr>
    <tr>
      <td>In     addition, Berlex Laboratories’ <font color="blue">fludarabine competes with</font> Nipent in the     <font color="blue">leukemia market</font>, and Dacogen <font color="blue">faces potential competition from</font> Pharmion’s     Vidaza, which was <font color="blue">approved by</font> the FDA in the first half of 2004</td>
    </tr>
    <tr>
      <td>Many of these <font color="blue">competitors</font> have <font color="blue">significant</font>ly greater experience than we do     in  developing products, undertaking pre-clinical testing and clinical     trials, obtaining FDA and other <font color="blue"><font color="blue">regulatory</font> approval</font>s, and <font color="blue">manufacturing</font> and     <font color="blue">marketing products</font></td>
    </tr>
    <tr>
      <td>Accordingly, our <font color="blue">competitors</font> may succeed in obtaining     <font color="blue">patent protection</font>, receiving FDA approval or <font color="blue">commercializing products</font> before     we do</td>
    </tr>
    <tr>
      <td>If we <font color="blue">commence sales</font> of our <font color="blue"><font color="blue">product candidate</font>s</font>, we will be competing     against  companies  <font color="blue">with greater marketing expertise</font> and <font color="blue">manufacturing</font>     <font color="blue">capabilities</font>, areas in which we have limited or no experience</td>
    </tr>
    <tr>
      <td>We <font color="blue">also face intense competition from</font> other companies for <font color="blue">collaborative</font>     <font color="blue">relationships</font>, for establishing <font color="blue"><font color="blue">relationships</font> with</font> academic and research     <font color="blue">institutions</font>, and for licenses to <font color="blue">proprietary</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitive</font> position</font>s in our <font color="blue">generic drugs</font> are uncertain and subject to     risks</td>
    </tr>
    <tr>
      <td>The market for <font color="blue">generic drugs</font>, including the pricing for generic     drugs, is extremely <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>As a result, unless our <font color="blue">generic drugs</font> are     the first or among the initial few to launch, there is a high risk that our     products would not gain <font color="blue">meaningful</font> market share, or we would not be able to     maintain our price and continue the product line</td>
    </tr>
    <tr>
      <td>Moreover, marketing of     <font color="blue">generic drugs</font> is also subject to <font color="blue"><font color="blue">regulatory</font> approval</font>, and if we were not     able to obtain <font color="blue">such approval</font> before our <font color="blue">competitors</font>, we would lose our     <font color="blue">competitive</font> advantage</td>
    </tr>
    <tr>
      <td>Failure to maintain our <font color="blue"><font color="blue">competitive</font> position</font> could     have a material adverse effect on our business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">pharmaceutical</font> industry</font> in general and the oncology sector in particular     is subject to <font color="blue">significant</font> and <font color="blue">rapid technological</font> change</td>
    </tr>
    <tr>
      <td><font color="blue">Developments </font>by     <font color="blue">competitors</font> may render our <font color="blue"><font color="blue">product candidate</font>s</font> or <font color="blue">technologies</font> obsolete or     non-<font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may succeed in developing <font color="blue">technologies</font> or products that are     more <font color="blue">effective</font> than ours</td>
    </tr>
    <tr>
      <td>Additionally, our products that are <font color="blue">under patent</font>     protection face intense competition from <font color="blue">competitors</font>’ <font color="blue">proprietary</font> products</td>
    </tr>
    <tr>
      <td>This competition may increase as <font color="blue">new products</font> enter the market</td>
    </tr>
    <tr>
      <td>A number of our <font color="blue">competitors</font> have <font color="blue">substantially</font> more capital, research and     <font color="blue">development</font>, <font color="blue">regulatory</font>, <font color="blue">manufacturing</font>, marketing, human and other resources     and experience than we have</td>
    </tr>
    <tr>
      <td>As a result, our <font color="blue">competitors</font> may:       ·       develop products that are more <font color="blue">effective</font> or less costly than any of     our current or <font color="blue">future products</font> or that render our <font color="blue">products obsolete</font>;       ·       produce and market their products more <font color="blue">successfully</font> than we do;       ·       establish superior <font color="blue">proprietary</font> positions; or       ·       obtain FDA approval for labeling claims that are more favorable than     those for our products</td>
    </tr>
    <tr>
      <td>We will also face increasing competition from lower-cost generic products     after <font color="blue">patents on</font> our <font color="blue">proprietary</font> products expire</td>
    </tr>
    <tr>
      <td>Loss of <font color="blue">patent protection</font>     typically leads to a <font color="blue">rapid decline</font> in sales for that product and could     affect our future results</td>
    </tr>
    <tr>
      <td>As <font color="blue">new products</font> enter the market, our products     may become       41     ______________________________________________________________________       obsolete  or  our  <font color="blue">competitors</font>’ <font color="blue">products may</font> be more <font color="blue">effective</font> or more     <font color="blue">effective</font>ly marketed and sold than our products</td>
    </tr>
    <tr>
      <td><font color="blue">Technological </font>advances,     <font color="blue">competitive</font> forces and loss of <font color="blue">intellectual</font> property protection rights for     our <font color="blue">products may</font> render our <font color="blue">products obsolete</font></td>
    </tr>
    <tr>
      <td>We are developing <font color="blue">products based upon compounds</font> that may be <font color="blue">covered by</font>     patents  held  by <font color="blue">third parties</font> that are expected to expire or already     expired</td>
    </tr>
    <tr>
      <td>These <font color="blue">compounds may also</font> be the subject of method, <font color="blue">formulation</font>, and     <font color="blue">manufacturing</font> process patents held by <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>If these patents do not     expire as anticipated or are expanded in scope, we will not be able to     develop our <font color="blue">products as</font> planned</td>
    </tr>
    <tr>
      <td>We developed, or are in the process of developing, and are planning to     market  several  generic and <font color="blue">proprietary</font> <font color="blue">formulation</font> products <font color="blue">based on</font>     <font color="blue">existing compounds</font></td>
    </tr>
    <tr>
      <td>Specifically, <font color="blue">with respect</font> to our generic products, we     received approval of ANDA’s  for our <font color="blue">generic mitomycin</font> for solid tumors for     our generic <font color="blue">paclitaxel</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">proprietary</font> <font color="blue">formulation</font> <font color="blue">technology</font> is a platform <font color="blue">technology</font> that employs     the use of an inert chemical excipient, cyclodextrin, combined with a drug</td>
    </tr>
    <tr>
      <td>Most  anti-cancer  drugs  are cytotoxic, and most must be <font color="blue">administered</font>     <font color="blue">intravenously</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">proprietary</font> <font color="blue">formulation</font> <font color="blue">technology</font> is designed to     “shield”  the drug from the injection site, thus providing the patient     <font color="blue">protection from tissue ulceration</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">technology</font> may increase the relative     <font color="blue">solubility</font> of hard-to-dissolve anti-<font color="blue">cancer drugs</font>, hence increasing its     stability or shelf life</td>
    </tr>
    <tr>
      <td>However, each of these <font color="blue">benefits must</font> be supported     by <font color="blue">appropriate</font> data and <font color="blue">approved by</font> the FDA before we can make any claim in     this  regard</td>
    </tr>
    <tr>
      <td>Our <font color="blue">first product utilizing</font> our <font color="blue">proprietary</font> <font color="blue">formulation</font>     <font color="blue">technology</font>, a <font color="blue">formulation</font> of <font color="blue">generic mitomycin</font>, was <font color="blue">approved by</font> the FDA in     November 2002 as <font color="blue">Mitozytrex </font>(mitomycin for injection) for use in the therapy     of  <font color="blue">disseminate</font>d  <font color="blue">adenocarcinoma</font>  of the stomach or pancreas in proven     <font color="blue">combination</font>s with other approved chemo<font color="blue">therapeutic</font> agents and <font color="blue">as palliative</font>     treatment when other <font color="blue">modalities</font> have failed</td>
    </tr>
    <tr>
      <td>We cannot promote <font color="blue">Mitozytrex </font>as     providing any injection site ulceration protection, nor can we promote any     increased stability, <font color="blue">solubility</font> or shelf life extension, as compared to     <font color="blue">generic mitomycin</font></td>
    </tr>
    <tr>
      <td>We would be required to develop and submit <font color="blue">additional</font>     data to the FDA and receive FDA approval before we could make these claims</td>
    </tr>
    <tr>
      <td>Although no funds were spent in 2005, we have <font color="blue">previously</font> spent <font color="blue">approximately</font>     dlra6dtta4 million  on  developing and marketing our generic and <font color="blue">proprietary</font>     <font color="blue">formulation</font> products</td>
    </tr>
    <tr>
      <td>We have completed our pre-commercial <font color="blue">investment</font> in     developing Mitozytrex, and as of now we have not committed to an internal     budget for <font color="blue">additional</font> <font color="blue">proprietary</font> <font color="blue">formulation</font> <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>In     addition, we have no further generic drug <font color="blue">development</font> <font color="blue">commitment</font>s, as we are     <font color="blue">focusing on</font> developing our <font color="blue">proprietary</font> drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We  do  not hold any <font color="blue"><font color="blue">intellectual</font> <font color="blue">property rights</font></font> as to the underlying     <font color="blue">compounds on which</font> our generic or <font color="blue">proprietary</font> <font color="blue">formulation</font> products are     based</td>
    </tr>
    <tr>
      <td>We may in the <font color="blue">future evaluate</font> the <font color="blue">generic drug market</font> and develop     <font color="blue">additional</font> generic or <font color="blue">proprietary</font> products <font color="blue">based on</font> these compounds, which     may also be the subject of method, <font color="blue">formulation</font> and <font color="blue">manufacturing</font> process     patents held by <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">development</font> of generic or <font color="blue">proprietary</font>     <font color="blue">products may</font> also take place prior to, but in <font color="blue">anticipation</font> of, the expected     expiration  of existing <font color="blue">patent protection</font> for drugs developed by third     parties</td>
    </tr>
    <tr>
      <td>However,  if  existing <font color="blue">patent protection</font> on such products is     otherwise maintained, extended or expanded, it is unlikely that we will be     able to market our own generic or <font color="blue">proprietary</font> <font color="blue">formulation</font> products without     obtaining a <font color="blue">license from</font> the patent owner, which may not be <font color="blue">available on</font>     <font color="blue">commercially</font> acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>We may be subject to <font color="blue">product <font color="blue">liability</font></font> lawsuits and our <font color="blue">insurance may</font> be     inadequate to <font color="blue">cover damages</font></td>
    </tr>
    <tr>
      <td>Clinical trials and <font color="blue">commercial use</font> of our current and potential <font color="blue">products may</font>     expose  us to <font color="blue">liability</font> claims from the use or sale of these products</td>
    </tr>
    <tr>
      <td>Consumers, healthcare providers, <font color="blue">pharmaceutical</font> companies       42     ______________________________________________________________________       and <font color="blue">others selling such products might</font> make claims of this kind</td>
    </tr>
    <tr>
      <td>We may     experience <font color="blue">financial losses</font> in the future due to <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td>We  have obtained limited <font color="blue">product <font color="blue">liability</font></font> <font color="blue">insurance coverage</font> for our     products  and  clinical  trials,  under  which the <font color="blue">coverage limits</font> are     dlra10dtta0 million per occurrence and dlra10dtta0 million in the aggregate</td>
    </tr>
    <tr>
      <td>We do not     know whether this <font color="blue">coverage will</font> be adequate to <font color="blue">protect us</font> in the event of a     claim</td>
    </tr>
    <tr>
      <td>We may not be able to obtain or maintain <font color="blue">insurance coverage</font> in the     future at a <font color="blue">reasonable cost</font> or in <font color="blue">sufficient amounts</font> to <font color="blue">protect us</font> against     losses</td>
    </tr>
    <tr>
      <td>If <font color="blue">third parties</font> bring a successful <font color="blue">product <font color="blue">liability</font></font> claim or     series  of claims <font color="blue">against us</font> for <font color="blue">un<font color="blue">insured liabilities</font></font> or in excess of     <font color="blue">insured liabilities</font>, we may not have sufficient <font color="blue">financial resources</font> to     complete <font color="blue">development</font> or <font color="blue">commercialization</font> of any of our <font color="blue"><font color="blue">product candidate</font>s</font>     and our business and results of <font color="blue">operations</font> will be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>If we are unable to attract and retain <font color="blue">additional</font>, highly skilled personnel     required for the expansion of our <font color="blue">activities</font>, our business will suffer</td>
    </tr>
    <tr>
      <td>Further, our success is <font color="blue">dependent on key personnel</font>, including members of our     <font color="blue">senior <font color="blue">management</font></font> and <font color="blue">scientific staff</font></td>
    </tr>
    <tr>
      <td>If any of our <font color="blue">executive officers</font>     decides to leave and we <font color="blue">cannot locate</font> a qualified <font color="blue">replacement</font> in time to     allow a <font color="blue">smooth transition</font>, our business <font color="blue">operation may</font> be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>To <font color="blue">successfully</font> expand our <font color="blue">operations</font>, we will need to attract and retain     <font color="blue">additional</font> highly skilled individuals, particularly in the areas of sales,     marketing, clinical <font color="blue">administration</font>, preclinical and <font color="blue">development</font> research,     <font color="blue">manufacturing</font> and finance</td>
    </tr>
    <tr>
      <td>We <font color="blue">compete with</font> other companies for the services     of existing and potential employees, however to the extent these employees     <font color="blue">favor larger</font>, more <font color="blue">established employers</font>, we may be at a disadvantage</td>
    </tr>
    <tr>
      <td>Earthquake or other natural or man-made <font color="blue">disasters</font> and business <font color="blue">interruptions</font>     could <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> are vulnerable to interruption by fire, power loss, floods,     <font color="blue">telecommunications failure</font> and other <font color="blue">events beyond</font> our control</td>
    </tr>
    <tr>
      <td>In addition,     our  <font color="blue">operations</font>  are  susceptible to disruption as a result of natural     <font color="blue">disasters</font>  such  as  <font color="blue">earthquakes</font></td>
    </tr>
    <tr>
      <td>So far we have never experienced any     <font color="blue">significant</font> disruption of our <font color="blue">operations</font> as a result of <font color="blue">earthquakes</font> or other     natural  <font color="blue">disasters</font></td>
    </tr>
    <tr>
      <td>Although we have a <font color="blue">contingency recovery</font> plan, any     <font color="blue">significant</font> business <font color="blue">interruption could</font> cause delays in our drug <font color="blue">development</font>     and sales and harm our business</td>
    </tr>
    <tr>
      <td><font color="blue">Provisions  </font>in our <font color="blue">certificate</font> of <font color="blue">in<font color="blue">corporation</font></font>, bylaws and applicable     <font color="blue">Delaware </font><font color="blue">law may prevent</font> or discourage <font color="blue">third parties</font> or <font color="blue"><font color="blue">stockholders</font> from</font>     attempting to replace our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Anti-takeover provisions of our <font color="blue">certificate</font> of <font color="blue">in<font color="blue">corporation</font></font> and bylaws make     it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire us, even if doing so would be     <font color="blue">beneficial</font> to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>These provisions include:       ·       <font color="blue">authorization</font> of the issuance of up to 2cmam000cmam000 shares of our     <font color="blue">preferred stock</font>;       ·       <font color="blue">elimination</font> of <font color="blue">cumulative voting</font>; and       ·       <font color="blue">elimination</font> of <font color="blue">stockholder action by written consent</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">bylaws establish procedures</font>, including notice procedures, with regard to     the nomination, other than by or at the direction of our board of <font color="blue">directors</font>,     of <font color="blue">candidates</font> for election as <font color="blue">directors</font> or for <font color="blue">stockholder proposals</font> to be     <font color="blue">submitted at stockholder meetings</font></td>
    </tr>
    <tr>
      <td>We are also subject to Section 203 of the <font color="blue">Delaware </font>General Corporation Law,     an anti-takeover provision</td>
    </tr>
    <tr>
      <td>In general, Section 203 of the <font color="blue">Delaware </font>General     Corporation  Law  prevents  a  stockholder  owning  15prca  or  more of a     <font color="blue">corporation</font>’s  outstanding  voting  stock  from  engaging  in business     <font color="blue">combination</font>s with a <font color="blue">Delaware </font><font color="blue">corporation</font> for <font color="blue">three years following</font> the date     the stockholder acquired 15prca or more of a <font color="blue">corporation</font>’s outstanding voting     stock</td>
    </tr>
    <tr>
      <td>This <font color="blue">restriction</font> is subject to <font color="blue">exceptions</font>, including the approval of       43     ______________________________________________________________________       the board of <font color="blue">directors</font> and of the holders of at least two-thirds of the     outstanding shares of <font color="blue">voting stock</font> not owned by the <font color="blue">interested stockholder</font></td>
    </tr>
    <tr>
      <td>We  believe that the benefits of increased protection of our potential     ability  to <font color="blue">negotiate with</font> the proponents of unfriendly or unsolicited     proposals  to  acquire or <font color="blue">restructure us outweigh</font> the <font color="blue">disadvantages</font> of     <font color="blue">discouraging</font> those proposals because, among other things, negotiation of     those proposals could result in an improvement of their terms</td>
    </tr>
    <tr>
      <td>Nevertheless,     these provisions are expected to discourage different types of coercive     takeover practices and inadequate <font color="blue">takeover bids</font> and to <font color="blue">encourage persons</font>     seeking to acquire control of our company to first <font color="blue">negotiate with</font> us, and     may  have  the  effect  of preventing or <font color="blue">discouraging</font> <font color="blue">third parties</font> or     <font color="blue"><font color="blue">stockholders</font> from</font> attempting to replace our <font color="blue">management</font></td>
    </tr>
  </tbody>
</table>